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ABSTRACT 
Mycobacterium tuberculosis continues to be a leading cause of death by an infectious agent 
world wide with approximately two million deaths attributable to it annually. Once infected, the 
host mounts a robust Th1 type immune response that contains, but does not eliminate the 
bacteria.  A small percentage (5-10%) fail to contain the infection, develop active disease, and 
are contagious.  Most remain asymptomatic and are considered latently infected.  BCG, while the 
gold standard for vaccination, ultimately appears to limit disease, but not prevent infection.  In 
addition, chemotherapeutic treatment is long, requires multiple agents, and compliance is 
difficult to maintain.  With one third the world’s population infected, inadequate vaccine 
efficacy, and difficult treatment regimen, it is imperative that a better understanding of which 
factors are responsible for containment of the infection be achieved.  CD4 T cells are an essential 
component of the immune response that controls M. tuberculosis. CD4 T cells are able to both 
promote inflammation and dampen its effect.  As a pro-inflammatory Th1 cell, these cells secrete 
pro-inflammatory cytokines, participate in macrophage and dendritic cell activation and help 
prime CD8 T cells.  As regulatory T cells, CD4 T cells prevent autoimmunity and may act to 
protect surrounding tissue from immunopathologic damage. One main function of pro-
inflammatory CD4 T cells is IFN? production, however other cells can and do produce IFN?.  In 
addition, the role of regulatory T cells during infection and how they relate to disease 
progression has yet to be elucidated. The work presented in this dissertation provides a new 
model for addressing the role of IFN? from sources other than CD4 T cells, and addresses what 
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pro-inflammatory functions they may have in addition to IFN? production.  In addition, these 
studies address regulatory T cells and the anti-inflammatory effects of long term IL-12 treatment 
as well as Treg’s relationship to disease outcome in non-human primates.   
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TABLE OF CONTENTS 
PREFACE.................................................................................................................................XVI 
1.0 INTRODUCTION ............................................................................................................... 1 
1.1 PREVALENCE............................................................................................................ 2 
1.2 INFECTION OUTCOME .......................................................................................... 4 
1.3 TREATMENT ............................................................................................................. 5 
1.3.1 Sanitariums and Surgeries .............................................................................. 5 
1.3.2 Chemotherapeutics .......................................................................................... 6 
1.3.3 Direct observational therapy........................................................................... 7 
1.4 ANIMAL MODELS OF TB ....................................................................................... 8 
1.4.1 Non-human primates ....................................................................................... 8 
1.4.2 Mice ................................................................................................................... 9 
1.4.3 Rabbits (Mycobacterium bovis) ..................................................................... 10 
1.4.4 Guinea pigs ..................................................................................................... 10 
1.4.5 Zebra fish (Mycobacterium marinum) .......................................................... 10 
1.5 IMMUNE RESPONE TO M. TUBERCULOSIS INFECTION ............................ 11 
1.5.1 Infection and innate immune response ........................................................ 11 
1.5.2 Bridging the gap innate to adaptive immunity............................................ 13 
1.5.3 Adaptive immune response ........................................................................... 15 
 vii 
1.5.3.1 CD4 T cells........................................................................................... 16 
1.5.3.2 CD8 T cells........................................................................................... 23 
1.5.3.3 Other cells involved in the immune response................................... 23 
1.5.4 Granuloma...................................................................................................... 25 
2.0 STATEMENT OF THE PROBLEM ............................................................................... 27 
3.0 IFN?  FROM CD4 T CELLS IS REQUIRED FOR BACTERIAL CONTROL AND 
HOST SURVIVAL DURING ACUTE M. TUBERCULOSIS INFECTION......................... 29 
3.1 INTRODUCTION ..................................................................................................... 29 
3.2 MATERIALS AND METHODS.............................................................................. 31 
3.2.1 Animals ........................................................................................................... 31 
3.2.2 Probiotic pre-treatment of mice.................................................................... 31 
3.2.3 Isolation of donor cells ................................................................................... 31 
3.2.4 Adoptive transfer to recipient mice .............................................................. 32 
3.2.5 Aerosol infection of the mice ......................................................................... 32 
3.2.6 Harvest of organs for analysis....................................................................... 33 
3.2.7 Flow cytometry............................................................................................... 33 
3.2.8 RNA Isolation ................................................................................................. 34 
3.2.9 Real time quantitative PCR .......................................................................... 35 
3.2.10 Macrophage killing assay ............................................................................ 35 
3.3 RESULTS................................................................................................................... 36 
3.3.1 Building the adoptive transfer model........................................................... 36 
3.3.2 IFN?  from CD8 T cells is not sufficient to control M. tuberculosis infection 
in the absence of IFN?  from CD4 T cells ................................................................. 40 
viii 
3.3.2.1 IFN?  from CD4 T cells is required for host survival....................... 40 
3.3.2.2 In the absence of CD4 T cells that produce IFN? , bacterial growth 
is unchecked ....................................................................................................... 41 
3.3.2.3 CD4 T cells are required for an effective immune response........... 41 
3.3.2.4 In the absence of CD4 T cells, CD8 T cells are activated, but fewer 
are present in the lungs. .................................................................................... 42 
3.3.2.5 Adoptively transferred CD4 T cells produce pro-inflammatory 
cytokines ............................................................................................................. 43 
3.3.2.6 The quality of the CD8 T cell function is altered in the absence of 
IFN?  from CD4 T cells ...................................................................................... 44 
3.3.2.7 IL-2 from CD4 T cells may account for the poor immune response 
in animals lacking CD4 T cells. ........................................................................ 45 
3.3.3 IFN?  from CD4 T cells is necessary for antigen specific responses and 
directly affects the quality of the CD8 T cell response ........................................... 46 
3.3.3.1 IFN?  from CD4 T cells is required for control of bacterial burden
 47 
3.3.3.2 Without CD4 T cells, fewer cells are found at the site of infection 47 
3.3.3.3 Antigen specific CD4 and CD8 T cells can be detected in the lungs 
of experimental animals. ................................................................................... 47 
3.3.3.4 Cytokine production by antigen specific CD4 T cells...................... 50 
3.3.3.5 Antigen specific CD8 T cell functions ............................................... 51 
3.3.3.6 The effects of whole spleen equivalents on host survival ................ 53 
 ix 
3.3.4 T cell activation of macrophages to kill intracellular bacilli in the presence 
or absence of IFN? ..................................................................................................... 55 
3.4 DISCUSSION............................................................................................................. 57 
4.0 DELETION OF CD4+CD25+ REGULATORY T CELLS PRIOR TO M. 
TUBERCULOSIS INFECTION DOES NOT CHANGE INFECTION OUTCOME........... 60 
4.1 INTRODUCTION ..................................................................................................... 60 
4.2 MATERIALS AND METHODS.............................................................................. 62 
4.2.1 Animals ........................................................................................................... 62 
4.2.2 Probiotic Pre-treatment of RAG1-/- mice.................................................... 62 
4.2.3 Reconstitution of RAG 1-/- mice in the presence and absence of 
CD4+CD25+ cells ....................................................................................................... 63 
4.2.4 Reconstitution of RAG1-/- mice with only CD4+ T cells +/- CD4+CD25+ 
population ................................................................................................................... 63 
4.2.5 Antibody mediated depletion of CD25+ cells from C57BL/6 mice prior to 
infection....................................................................................................................... 64 
4.2.6 Aerosol infection............................................................................................. 64 
4.2.7 Harvest of organs for analysis....................................................................... 65 
4.2.8 Flow cytometric analysis of cellular infiltrate in lungs............................... 65 
4.3 THE PRESENCE OR ABSENCE OF CD25+ CELLS DOES NOT CHANGE 
OUTCOME OF INFECTION WHEN LYMPHOPENIC MICE ARE 
RECONSTITUTED WITH NAÏVE SPLENOCYTES................................................... 66 
4.3.1 Bacterial burden is not significantly different between animals that 
received splenocytes with Tregs and those that did not receive Tregs.................. 66 
 x 
4.3.1.1 The absence of Tregs does not affect survival.................................. 67 
4.3.1.2 Cellular infiltrate ................................................................................ 69 
4.4 RECONSTITUTION WITH ONLY CD4 T CELLS +/- CD25 CELLS .............. 71 
4.5 DEPLETION OF CD25+ T CELLS DURING ACUTE M. TUBERCULOSIS 
INFECTION ....................................................................................................................... 75 
4.5.1 Experimental set up ....................................................................................... 75 
4.5.2 Depletion of CD25+ cells does not affect bacterial burden over time ....... 75 
4.5.3 Depletion of CD25+ cells does not change the number of cells in each 
organ 76 
4.5.4 Lack of CD25+ cells did not change activation state or IFN?  production in 
either CD4 or CD8 T cells ......................................................................................... 78 
4.6 DISCUSSION............................................................................................................. 80 
5.0 LONG TERM IL-12 TREATMENT DURING EARLY M.TUBERCULOSIS 
RESULTS IN AN INCREASED FREQUENCY OF REGULATORY T CELLS AT SITES 
OF INFECTION ......................................................................................................................... 82 
5.1 INTRODUCTION ..................................................................................................... 82 
5.2 MATERIALS AND METHODS.............................................................................. 83 
5.2.1 Animals ........................................................................................................... 83 
5.2.2 IL-12 treatment .............................................................................................. 84 
5.2.3 Anti-TGF?  treatment .................................................................................... 84 
5.2.4 Aerosol infection............................................................................................. 84 
5.2.5 Organ harvest and cellular isolation ............................................................ 85 
5.2.6 Bacterial burden............................................................................................. 85 
 xi 
5.2.7 Flow Cytometry.............................................................................................. 85 
5.2.8 Statistics .......................................................................................................... 86 
5.3 RESULTS................................................................................................................... 86 
5.3.1 Long term IL-12 treatment during early M. tuberculosis infection results 
in a greater frequency of CD4+Foxp3+ T regulatory cells in wild type mice ...... 86 
5.3.1.1 Cellular infiltrate at the site of infection is decreased in IL-12 
treated animals when compared to those that received PBS......................... 87 
5.3.1.2 IL-12 treatment does not change bacterial burden ......................... 87 
5.3.1.3 IL-12 treatment results in fewer CD4 T cells producing IL-2........ 88 
5.3.1.4 IL-12 and Tregs................................................................................... 90 
5.3.1.5 TGF?  and IL-12 treatment................................................................ 92 
5.3.2 IL-12 immune suppression is independent of IL-10 ................................... 93 
5.3.2.1 IL-12 treatment of IL-10-/- mice did not affect bacterial burden .. 93 
5.3.2.2 IL-12 treatment decreases cellular infiltrate.................................... 93 
5.3.2.3 Tregs and TGF?+ CD4 T cells in IL-10-/- mice............................... 95 
5.3.3 Neutralization of TGF?  does not change IL-12 immune suppression ...... 96 
5.4 DISCUSSION............................................................................................................. 97 
6.0 REGULATORY T CELLS IN A CYNOMOLGUS MACAQUE MODEL OF M. 
TUBERCULOSIS INFECTION............................................................................................... 100 
6.1 INTRODUCTION ................................................................................................... 100 
6.2 MATERIALS AND METHODS............................................................................ 102 
6.2.1 Experimental animals. ................................................................................. 102 
6.2.2 Infection of NHP........................................................................................... 102 
 xii 
6.2.3 PBMC isolation ............................................................................................ 103 
6.2.4 BAL Cells ...................................................................................................... 103 
6.2.5 Necropsy of animals ..................................................................................... 103 
6.2.6 Isolation of cells from necropsy tissue........................................................ 103 
6.2.7 CD25 depletion from PBMCs ..................................................................... 104 
6.2.8 Lymphocyte proliferation assay ................................................................. 104 
6.2.9 Flow cytometry............................................................................................. 104 
6.2.10 Immunofluorescence tissue staining......................................................... 105 
6.2.11 ELISPOT for IFN? .................................................................................... 105 
6.2.12 Statistics ...................................................................................................... 106 
6.3 RESULTS................................................................................................................. 107 
6.3.1 Infection outcome is independent of age, gender and weight .................. 107 
6.3.2 CD4+ Foxp3+ cells are found within involved and not uninvolved lung and 
draining lymph node tissue ..................................................................................... 108 
6.3.3 CD4+Foxp3+ T cells are found within the lymphocyte cuff of the 
granuloma ................................................................................................................. 110 
6.3.4 Tregs migrate from peripheral blood to airways during early M. 
tuberculosis infection................................................................................................ 111 
6.3.5 Pre-infection levels of Tregs in PBMC correlate with clinical outcome . 112 
6.3.6 Foxp3+ cells affect proliferative responses in peripheral blood .............. 114 
6.4 DISCUSSION........................................................................................................... 116 
7.0 SUMMARY OF THE DISSERTATION....................................................................... 120 
BIBLIOGRAPHY..................................................................................................................... 127 
 xiii 
 LIST OF TABLES 
 
Table 1.  Summary of vital statistics and immunologic assays of all non-human primates used in 
this study. .................................................................................................................................... 107 
 xiv 
LIST OF FIGURES 
 
Figure 1 Design of adoptive transfer models and time line for set up.......................................... 39 
Figure 2 Murine survival after adoptive transfer and subsequent M. tuberculosis infection ....... 40 
Figure 3 Bacterial burden and cellular infiltrate in the lungs of experimental animals over time 42 
Figure 4. The frequency and activation status of T cells within the lung..................................... 43 
Figure 5. Cytokine production by T cells ..................................................................................... 45 
Figure 6. IL-2 expression in the lungs of reconstituted mice ....................................................... 46 
Figure 7. Bacterial burden, total cell numbers and T cells in an adoptive transfer model using 
whole spleen equivalents .............................................................................................................. 49 
Figure 8. Antigen specific cytokine production by CD4 T cells .................................................. 51 
Figure 9. Antigen specific CD8 T cell function............................................................................ 53 
Figure 10. Survival of mice reconstituted +/- CD4 T cells and splenic equivalents .................... 54 
Figure 11. Macrophage killing assay ............................................................................................ 57 
Figure 12. Adoptive transfer, bacterial burden and survival ........................................................ 69 
Figure 13. T cell frequency and activation in the lungs of mice reconstituted with naïve 
splenocytes.................................................................................................................................... 70 
Figure 14. Monocytes found within the lung of reconstituted M. tuberculosis infected mice ..... 71 
Figure 15. Adoptive transfer of CD4 T cells +/- CD25+ cells ..................................................... 74 
 xv 
Figure 16. Bacterial burden and cellular infiltrate in lungs of RAG1-/- mice reconstituted with 
CD4 T cells +/- Tregs ................................................................................................................... 74 
Figure 17. Depletion of CD25+ cells in C57BL/6 mice ............................................................... 76 
Figure 18. CFU and total cell number per organ .......................................................................... 77 
Figure 19 T cell activation in the lungs and draining lymph node ............................................... 79 
Figure 20. IFN? production by CD4 and CD8 T cells in lung and lymph node ........................... 79 
Figure 21. Cellular infiltrate and bacterial burden in IL-12 and PBS treated wild type mice ...... 88 
Figure 22. IL-2 producing CD4 T cells in the lungs and lymph nodes ........................................ 89 
Figure 23. Regulatory T cells and IL-12 treatment....................................................................... 92 
Figure 24. CD4+TGF?+ cells and IL-12 treatment ...................................................................... 93 
Figure 25. CFU and total cell numbers in IL-12 treated IL-10-/- mice ........................................ 94 
Figure 26. Frequency of Tregs and CD4+TGF?+ cells in IL-12 treated  IL-10-/- mice .............. 96 
Figure 27. Regulatory T cells are enriched in involved lung tissue and lymph node................. 109 
Figure 28. Cellular surface markers on Tregs............................................................................. 110 
Figure 29. Regulatory T cells in granulomas.............................................................................. 111 
Figure 30. Tregs in PBMC and airways during M. tuberculosis infection ................................. 113 
Figure 31. Tregs inhibit PBMC proliferation ............................................................................. 116 
 xvi 
PREFACE 
Thank you to my mentor Joanne Flynn, without whom this work would not have been possible.  
Her direct, straightforward and passionate approach to life and science is awe-inspiring.  She is 
truly training independent scientist! Thank you to the current and former members of the Flynn 
lab.  You challenge me every day to be a better scientist. 
I am very grateful for the time and commitment of my committee, Robert Hendricks, 
Jerry Nau, Karen Norris and Anuradha Ray.  Their input and suggestions have proved 
invaluable, especially when the data weren’t as exciting as I had hoped.  
No one embarks on this journey and finishes without support. I’d like to thank my family 
and friends for their continued love and support.  In particular, my MoM and Dad, Kathy and 
Don Green, thanks for all the Sunday dinners and fun times.  My brothers Jason and Ben, my 
sister-in-law Mary, and nephew Brad, thank you for putting up with the mad scientist.  I’d like to 
thank “The Tribe” you know who you are I’m looking forward to more outings this fall.  Thank 
you to Kris and Gibby and Patricia for all the times I was climbing the walls, you listened and 
knew when it was time to make me go skiing and running.   
 
 1 
1.0  INTRODUCTION 
Mycobacterium tuberculosis (M. tuberculosis), the acid-fast bacillus responsible for human 
tuberculosis (TB) is an exquisite pathogen that has been evolving with the human race for 
millennia.  Called “phthisis” by the ancient Greeks, the long history of tuberculosis and man has 
worked its way into art and literature from the art of the Egyptians to such well known authors as 
Emily Bronte and Jane Austen [1].  At one point it was even considered desirable and 
fashionable to look as if one had “consumption.”  Numerous sufferers of TB were used as muses 
for artists’ renderings of ancient scenes such as Botticelli’s “The Birth of Venus” [1].  M. 
tuberculosis DNA has been isolated from mummies found with bone disease, dating back 9000 
years [2].  In addition to its long history with man, TB was also found on almost every continent.  
M. tuberculosis-mediated bone disease, such as Potts disease, has been found in mummies from 
Israel (9000 y/o) [2], Egypt (5000 y/o), and Peru (1000 y/o) [3] and descriptions of TB have been 
found in texts from India and China dating back as long as 3300 and 2300 years ago respectively 
(reviewed in [4]).  With such an extensive distribution among so many different cultures for 
thousands of years, it is not hard to understand why one third of the world is estimated to harbor 
this infection today [5].  As M. tuberculosis continued to persist throughout human evolution, in 
western cultures (Western Europe and North America), TB reached it zenith during the 18
th
 and 
first half of the 19
th
 centuries.  Its primary victims were young adults.  Their untimely death is 
perhaps what fueled the romanticized ideal of the wan, pale victim of TB.  The “White plague” 
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began to wane in the middle of the 19
th
 century.  The reduction in the number of people with TB 
at that time has been attributed to natural selection of a more resistant population as well as 
better sanitation and nutrition [6].  However, a definitive answer has never been determined.  
Until 1882, the cause of TB was largely unknown, on one hand thought to be inheritable 
since multiple members seemed to be succumb within a family unit, on the other hand 
hypothesized to be caused by an infectious agent [4].  Robert Heinrich Koch settled the debate 
when he presented his “Die Aetiologie der Tuberculose” at the Berlin Physiological Society.  He 
had identified the tubercle bacillus, shown that it could and did cause disease and was able to 
isolate it again from the infected tissues.  Thus, not only did he discover the cause of 
tuberculosis, he also presented the criteria still used today to determine a disease is caused by an 
infection, Koch’s postulates [4].  
In the early 20
th
 century, Clemens Freiherr von Pirquet documented reactions to 
subcutaneously administered M. tuberculosis-derived proteins in asymptomatic people, thus 
coining the term latent tuberculosis [7].  Charles Mantoux’s use of a cannulated needle to 
provide the tuberculin derivative, in conjunction with the development of purified protein 
derivative (PPD) by Florence Seibert, was the advent of what is our modern day TB skin test [4].  
The development of this test allowed for more wide spread surveillance of M. tuberculosis 
prevalence among varied populations.   
1.1 PREVALENCE 
The decline in TB related deaths that started in the mid 19
th
 century continued, particularly in 
Western Europe and North America, until the advent of the HIV/AIDS epidemic in the 1980’s 
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[8].  With the HIV epidemic, global rates of TB rose for the first time in decades.  The WHO 
estimates are 9 million new cases of TB in 2007, with 15% due to coinfection with HIV [9].  
Globally, the WHO estimates that one third of the world’s population (~2 billion people) are 
currently infected with M. tuberculosis. Of those individuals infected with the bacilli, 1.7 million 
died from the disease in the 2007 [5].  It is the developing world that bears the brunt of the 
burden of TB. Thirteen of the 15 countries with the greatest incidence of TB infection are in 
Africa and a direct correlation with HIV co-infection has been shown [10].  HIV infection 
increases the risk of developing active disease from 10% per life time to 10% per year [5].  
While approximately 15% of those who get active disease are HIV+, those with co-infection 
account for almost 23% of the mortality rate attributed to TB [10].  
In addition to the complication of HIV/TB co-infection, the incidence of multi-drug 
resistant (MDR)-TB and extensively drug resistant (XDR)-TB has continued to increase, 
particularly in Asia and the former Soviet Union.  Multi-drug resistance is defined as resistance 
to the two front-line drugs isoniazid (INH) and rifampin (RIF) and extensively drug resistance 
defined as M. tuberculosis that is resistant to INH, RIF, the fluoroquinolones and one of the three 
second-line injectable drugs [11].  Many cases of XDR-TB are essentially untreatable.  In the US 
and Western Europe, MDR-TB accounts for fewer than 3% of cases, whereas in Africa rates as 
high as 14% of cases are MDR [11, 12].  In Asia, specifically certain parts of China, MDR-TB 
accounts for up to 7.3% of the total TB cases.  In the former Soviet Union, the incidence of 
MDR-TB ranges from 6.8% in Georgia to as high as 22% in Azerbaijan.  Even more alarmingly, 
in the former Soviet Union, the incidence of XDR-TB among the MDR-TB accounts for from 
4% in Armenia to almost 24% in Estonia [9].  WHO estimates that 40,000 new cases of XDR-
TB emerge each year.  MDR-TB and XDR-TB arise when a course of chemotherapy is not 
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completed and are thought to be indicators of TB control failures at the national level.  Lack of 
infrastructure to maintain the supply of chemotherapeutic agents, patient non-compliance with 
such a long course of treatment and loss of adequate public health services have been shown to 
be the root cause of the rise in global MDR and XDR-TB [8, 12-14].   
1.2 INFECTION OUTCOME 
Exposure to M. tuberculosis does not guarantee infection, since only 20-30% of those exposed 
will develop a positive tuberculin skin test (TST).  Infection is defined as a positive result for 
either a TST or IFN? release assay (IGRA) [15].  TST-negative exposed persons must somehow 
prevent establishment of infection (and the resulting T cell response that is detected by TST).  A 
few of the individuals that become infected (5-10%), will develop signs and symptoms of active 
disease within the first two years post infection (primary TB) and are contagious.  Active disease 
is classified as a positive TST or IGRA and clinical signs of disease (positive sputum culture, 
coughing, weight loss, or evidence of disease by chest x-ray).  90-95% of M. tuberculosis 
infected individuals mount an effective, non-sterilizing immune response that walls off the 
bacilli within discrete structures called granulomas.  When infection is controlled, with no 
clinical manifestation of disease, it is considered a latent infection.  A majority will control the 
infection for life, and carry a 10% per year risk of developing active disease later in life 
(reactivation TB).  Immune compromise by infection (HIV), immunomodulatory therapies (e.g. 
TNF-neutralizing antibodies as a treatment for inflammatory diseases) and advanced age 
increases the risk for reactivation [5].  
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In the simplest interpretation, M. tuberculosis infection outcome appears to result in 
either an active or latent infection as first proposed by von Pirquot when he described latent 
infection [7].  When the various manifestations of disease are evaluated however, a picture 
emerges that more closely resembles those proposed in a review by Barry et al. and Lin et al. 
[16, 17].  It seems that active disease and latent infection are not two distinct outcomes, but are a 
spectrum of outcomes ranging from clearance or dormant infection to the development of 
fulminant disease.   
1.3 TREATMENT 
1.3.1 Sanitariums and Surgeries 
Prior to the development of the first chemotherapies to treat tuberculosis, patients with 
TB were quarantined in sanitariums.  The prescription was for rest, plentiful rich food, sunshine 
and isolation from the stresses of everyday life.  The first of these sanitariums in the United 
States was set up by Edward Livingston Trudeau at Saranac Lake, New York [18].   
The quest for a mechanical solution was also sought and it was hypothesized that if rest 
for the body was beneficial perhaps so would be rest for the diseased lungs.  Patients were 
subjected to pulmonary collapse therapy in which sandbags were used to splint one side of the 
chest [4].  Others attempted surgical intervention included therapeutic pneumothorax by 
artificially introducing air into the pleural space to collapse the lung so it could “rest”.  This 
procedure may have been successful if only because it resulted in cavity closure and conversion 
to sputum negative (i.e. no bacilli were seen in sputum samples) [19].  In yet another surgical 
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variation, thoracoplasty (removal of part of the rib cage) was also tried.  This was at the time 
considered safer since it did not require entering the pleural cavity.  Again the success of this 
procedure may be attributable to cavity closure and not a decreased bacterial load [20].  Still 
today, in areas where MDR-TB is endemic, lung resection of cavitary lesions or destroyed tissue, 
in combination with chemotherapy is the treatment of choice [21]. 
1.3.2 Chemotherapeutics 
In the 1940s the first chemotherapeutic compounds, streptomycin and para-amino 
salicylic acid (PAS), were discovered.  Streptomycin was reported by Schatz et al in 1944 as 
having antibiotic activity against bacteria [22] and it was the first drug to be used to successfully 
treat TB.  It was quickly apparent that M. tuberculosis could become resistant, but this could be 
overcome by using it in combination with PAS [23].  Streptomycin inhibits protein synthesis 
where as PAS most likely interferes with cell wall synthesis.  Today, both streptomycin and PAS 
are considered second line drugs for treatment of TB [14]. 
While the discovery of streptomycin and PAS revolutionized the treatment of TB, both 
were only bacteriostatic. It was not the discovery of isoniazid (INH) in 1952 that the first 
bactericidal compound was introduced.  An added benefit of INH was that it is administered 
orally [24].  In combination with Streptomycin and PAS, INH became part of the standard drug 
regimen [25].  INH remains a front line drug and in the developed world is given prophylacticly 
to patients with latent infections [14].  
Pyrazinamide was also introduced in 1952.  It is active against non-replicating bacteria, 
but is unable to provide a sterilizing course of treatment by itself.  The mechanism of action 
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against the bacillus is not well defined, but the drug is thought to disrupt the membrane transport 
of Pyrazinoic acid [25]. 
In the 1960s further strides were made with the introduction of Ethambutol.  Ethambutol 
interferes with construction of the arabinogalactan layer of the cell wall, but the exact 
mechanism has yet to be defined.  It replaced PAS in the standard drug therapy combination, 
reducing toxicity and decreasing the length of treatment from 24 to 18 months [18]  
In 1966, rifampicin  (RIF) was shown to be effective against M. tuberculosis.  Today it is 
a cornerstone of the modern first line drug cocktail and inhibits transcription [26].  Addition of 
RIF decreased treatment from 18 months to 9 months.  Treatment length was further reduced to 6 
months by the addition of PZA to the cocktail of INH and RIF [18].   
Currently, the cornerstone of MDR-TB treatment is the fluoroquinolones.  A class of 
broad-spectrum antibiotics, these compounds have good oral bioavailability and are bactericidal 
against M. tuberculosis.  In addition, these compounds have not been shown to have cross 
resistance with the anti-mycobacterial drugs and newer classes of these compounds are being 
investigated as a replacement in first line anti-TB drug combination therapy [27].   
1.3.3 Direct observational therapy 
The advent of chemotherapeutic interventions revolutionized the treatment of TB.  
However, the large number of patients, the length of treatment that required hospitalization, and 
lack of enough hospital beds in some endemic areas presented a need for outpatient care.  In 
randomized trials, those treated at home had a higher rate of non-compliance with treatment. 
Therefore directly observed therapy (DOT) was implemented.  Those being treated for TB were 
directly observed taking their medicine by trained personnel.  This is a WHO program, where 
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commitment from the government of each nation is required and criteria for drug delivery must 
be met.  DOT therapy became direct observational therapy short course (DOTs) when the 
treatment cocktails regimens reduced time of treatment [28].  
1.4 ANIMAL MODELS OF TB 
Humans are genetically heterogeneous and this diversity results in a spectrum of disease from 
asymptomatic latent infection, subclinical infection, active pulmonary disease to extrapulmonary 
TB (reviewed in [17]).  The study of TB in humans is limited by how the disease can be 
visualized (X-ray, MRI, CT-PET scans) and the types of samples that are safely and easily 
obtained such as peripheral blood and bronchial alveolar lavage (BAL).  In addition, the duration 
of infection, size of inoculum, strain with which they were infected and the immune and co-
infection status of the host at the time of M. tuberculosis infection are not known, all factors that 
can influence disease outcome.  Fortunately multiple animal models are available for studying 
the immune response to M. tuberculosis. 
1.4.1 Non-human primates  
Non-human primate is the only animal model of M. tuberculosis infection that can recapitulate 
the spectrum of latent and active disease seen in human [29].  The desired disease outcome can 
be manipulated by the size of the inoculum at the time of infection (i.e. the higher the dose, the 
more likely the NHP will develop active disease) [30, 31].  In this model, M. tuberculosis is 
introduced to the lung by bronchoscope, but aerosol delivery is also used by some groups [32]. 
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NHP infected with M. tuberculosis also develop the entire range of diverse granulomas 
seen in humans [30].  Sufficient reagents are available for research analysis of immunologic 
factors and many human reagents cross react.  This model has two main drawbacks: the animals 
are as genetically diverse as the human population, there is both inter- and intra- monkey 
variability is not uncommon.  In addition, this model is expensive to maintain.    
1.4.2 Mice 
The murine model of M. tuberculosis is the most widely used model for studying TB.  The 
availability of inbred, knockout, knock-in and transgenic animals in conjunction with a large 
array of reagents make this an ideal system to manipulate.  This system has proven useful for 
identification of immune factors that are essential for control of M. tuberculosis.  All mice are 
susceptible to M. tuberculosis meaning they can be infected and develop disease that eventually 
proceeds to death.  Some strains can control infection for longer periods of time and are 
considered more resistant (e.g.C57BL/6 mice control infection for longer than DBA mice on a 
C3H background [33].)  Similar to humans, immune competent mouse strains are able to control 
the infection without signs of disease for up to a year.  However, mice carry a high bacterial 
burden in the lungs (~1x10
6
 CFU/lung) and have a chronic progressive infection and no latent 
form.  Murine granulomas differ from those found in humans and the NHP model.  In addition 
granulomas in this model do not result in caseous necrosis or cavitary lesions.  Murine 
granulomas are loose aggregates of cells.  Multiple routes of infection have been used, but the 
most physiologically relevant is by aerosolization of virulent M. tuberculosis directly into the 
airways [34].   
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1.4.3 Rabbits (Mycobacterium bovis) 
Rabbits are naturally resistant to M. tuberculosis and while rabbits develop granulomas that can 
become cavitary, the lesions eventually heal.  However, they are very susceptible to 
Mycobacterium bovis (M. bovis).  Rabbits infected with M. bovis develop granulomas that 
resemble human granulomas in structure and environment and are the only model besides NHP 
to develop cavitary lesions [35].  Fewer reagents are available for studies in rabbits than are 
available in the mouse model.  In addition, the rabbits require more space and are more costly to 
maintain than mice [36]. 
1.4.4 Guinea pigs 
Guinea pigs are highly susceptible to M. tuberculosis and were used to identify M. tuberculosis 
as the etiologic agent of TB [27].  In addition, it was the model used to show the antibacterial 
properties of INH and ethambutol [27].  Granulomas formed can be highly organized and 
caseous necrosis is often seen [37].  A majority of animals used are out-bred; inbred strains are 
limited and few immunologic reagents are available for research in this model [34].   
1.4.5 Zebra fish (Mycobacterium marinum) 
Zebra fish are naturally susceptible to Mycobacterium marinum (M. marinum) a close 
relative of M. tuberculosis.  Upon infection with M. marinum, zebra fish mount an adaptive 
immune response and develop caseating granulomas [38].  However, the greatest contributions 
of the model have been the ability to visualize interactions between the mycobacteria and innate 
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immune cells in the transparent juvenile zebra fish.  This model has been used to show that M. 
marinum is capable of super-infection [39] and infected macrophages migrate toward each other 
and can swap intracellular bacteria [40, 41].  As this model has developed, inbred and knockout 
strains have been established, and forward genetics can be used to identify host factors important 
in control of infection.  This model is relatively inexpensive to maintain and the generation time 
for new mutants is very short. 
1.5 IMMUNE RESPONE TO M. TUBERCULOSIS INFECTION 
1.5.1 Infection and innate immune response 
When a person with active tuberculosis coughs, M. tuberculosis bacilli are released in 
aerosolized droplets.  The aerosolized droplets are inhaled and the bacilli enter the airways.  
Inside the airways, innate immune cells such as macrophages (M?) and dendritic cells (DC) 
phagocytose M. tuberculosis and begin a complex of series of host-pathogen interactions. 
Phagocytosis of M. tuberculosis is mediated by multiple receptors such as complement 
receptor type 1 and 3, [42, 43], the mannose receptor [44, 45], and by directly interacting with 
surfactant protein-A and binding its receptors [46, 47].  The reasons why M. tuberculosis has 
developed multiple mechanisms of entry into host cells are not well understood.  It may be that 
by using different receptors, entry into specific cells may benefit the bacilli by initiating unique 
cytokine secretion patterns or facilitating spread of the bacteria via migration of macrophages or 
dendritic cells [48].  
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Once inside the phagosome, M. tuberculosis has evolved several mechanisms to 
circumvent the host immune response and make the intracellular environment more hospitable.  
M. tuberculosis can escape the phagosome and this requires the expression of the ESX bacterial 
secretion system [49]; however, the concept that M. tuberculosis can escape to the cytosol is 
controversial at this time, and the physiological relevance of the in vitro data on this issue is not 
known.  Multiple components of the cell wall, such as trehalose 6,6’-dimycolate (TDM, also 
known as cord factor) and lipoarabinomannan, induce specific cytokines, inhibit 
polymorphonuclear leukocyte migration, scavenge oxygen free radicals, inhibit protein kinase C 
and inhibit transcriptional activation of IFN? inducible genes [50-52].   
Fusion of the phagosome to lysosome is required for bactericidal activity in M?s.  M. 
tuberculosis cell wall contains anionic trehalose glycolipids that can prevent phago-lysosome 
fusion (reviewed in [53]).  M. tuberculosis can alter the acidity of phagosomes and lysosomes.  
M. tuberculosis can produce excess ammonia, which acts as an alkalizing agent, thus reducing 
the ability of lysosomal enzymes to properly function [54, 55].  In addition, the bacilli have been 
reported to inhibit proton ATPase-dependent acidification of the phagosome and phago-
lysosome [56].  Another strategy of the bacillus is to block phagosome maturation.  M. 
tuberculosis promotes retention of Rab5A on the surface of phagosomes but has impaired 
recruitment of Rab5 effectors EEA1 and hVPS34 preventing phagosome maturation [57-59].  In 
addition, phagosomes containing the bacilli recruit and retain tryptophan-aspartate containing 
coat protein (TACO), and this inhibits trafficking to the lysosome [60].  Reactive oxygen species 
and reactive nitrogen intermediates are required for killing intracellular bacteria within M?s.  M. 
tuberculosis is able to neutralize oxidative radicals by producing superoxide dismutase in 
response to the sensor oxyR [61, 62].  Finally, once activated, M?s initiates the inflammasome, 
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resulting in IL-1? processing and phagosome maturation.  M. tuberculosis directly interferes 
with IL-1? processing by secreting the zinc metalloprotease (ZmpA) [63, 64].  Together these 
mechanisms of immune modulation allow the bacteria to grow for an extended period of time 
within phagocytes. 
In the mouse model of M. tuberculosis infection, the bacilli expand exponentially in the 
lungs, reaching a level of ~5x10
6
 CFU/lung, until initiation of the adaptive immune response at 
approximately 21 days post infection (p.i.) [65].  M. tuberculosis infection is eventually 
recognized.  Recognition of the infection is mediated by toll-like receptors (TLRs) and it has 
been shown that the TLR adaptor molecule, myeloid differentiation factor 88 (MyD88) is 
required for host survival [66].  In particular the heterodimer of TLR2 with TLR1 or TLR6 as 
well as TLR9 and TLR4 have been implicated [67-71].  Interestingly, TLR2 has been shown to 
directly interact with ESAT6 [72].  Recognition of bacterial products by TLRs results in the 
initiation of the immune response and an increased production of reactive oxygen species, 
reactive nitrogen intermediates, anti-microbial peptides and cytokine production.[73-75].  
However, innate immunity is not sufficient to control infection without the initiation and priming 
of an adaptive response.   
1.5.2 Bridging the gap innate to adaptive immunity 
Progression from an innate immune response to initiation of the adaptive response begins at the 
site of infection where infected M?s and DCs produce multiple cytokines and chemokines [69, 
76].  The character and quality of the adaptive immune response is influenced by the cytokines 
present during priming.  Pro-inflammatory cytokines IL-1? (processed during initiation of the 
inflammasome), IL-12, TNF and IFN? promote a T- helper 1 phenotype that is optimal for 
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infection control in both mice and humans [77-81].  During early infection, an influx of IL-17 
producing cells (?? T cells and Th17 cells) has been reported [82, 83].  They are induced by IL-
23 and thought to play a role in leukocyte recruitment to the infection site, but are not required 
for host survival [82, 83].  Additional cytokines such as IL-4, IL-13 and IL-10 skew the immune 
response toward a Th2 phenotype.  Th2 type responses are associated with less than optimal 
control of M. tuberculosis infection [84-86], although most persons (and mice) with TB disease 
have strong Th1 responses so this is not strictly a Th1/Th2 disease.  In addition, it has been 
hypothesized that the immune response to mycobacterial infection in children is skewed toward a 
Th2 type response and this may be the reason for an increased risk of developing disseminated 
disease [87], however, this is controversial.   
Multiple factors influence the type of immune response to M. tuberculosis.  One 
determinant of infection control is the immune status of the host, for instance the immune 
response may differ between an immune competent adult, a very young child and an individual 
co-infected with HIV [87-89].  Additionally, bacterial components also influence the type of 
immune response elicited with some that promote pro-inflammatory cytokine production, and 
several that promote anti-inflammatory cytokine production [69, 90].  The combination of these 
factors and their influence on the balance between pro-inflammatory and anti-inflammatory may 
mean the difference between active disease and latent infection in humans.   
 Resident alveolar M?s are presumably one of the first cell types to be infected with M. 
tuberculosis and in response produce CCL2, CCL3 and CCL5, where as monocyte derived M?s 
(those thought to have migrated from the periphery) produce CCL2, CCL3, CCL4 And CCL5 
[91].  M?s are thought to remain at the site of infection, however studies of M. marinum 
challenge this strict view.  Infected M?s are able to migrate toward other infected M?s and are 
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able to exchange intracellular bacteria and may contribute to dissemination of the bacilli [39, 41]. 
One can hypothesize that chemokines may contribute to infected M? migration that may be 
beneficial for the establishment of a persistent infection. 
While M?s remain at the site of infection and possibly contribute to bacterial 
dissemination, DCs may also contribute to dissemination but also bridge the gap between innate 
and adaptive immunity.  Once infected, DCs up regulate the expression of CXCR4 and CCR7 
which are chemokine receptors necessary for migration to draining lymph nodes [92].  Recently 
an alternate splice variant of IL-12 receptor ?1 has been shown to enhance M. tuberculosis 
infected DC migration from the lung to the lymph nodes [93].  As DCs migrate and mature the 
ability to phagocytose is down regulated, expression of costimulatory molecules (i.e. MHCII, 
CD80, CD86) increased, and cytokines that aid in T cell priming produced [94].   
1.5.3 Adaptive immune response 
When compared to the immune response to other infections, the initial response to M. 
tuberculosis is delayed [95, 96].  Despite this delay, exponential bacterial growth (at least in the 
murine model) is halted when primed T cells migrate back to the site of infection indicating the 
adaptive immune response acts to control and contain the bacterium [97].   
Control of M. tuberculosis infection is dependent upon initiation of the adaptive immune 
response in both mice and humans [98-100].  DC migration from the site of infection to the 
draining lymph nodes both contributes to bacterial dissemination and initiates the priming of the 
adaptive response [101].  Delaying the DC migration (by DC depletion) exacerbates disease 
outcome and decreases control of the infection by CD4 T cells [102]. 
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1.5.3.1  CD4 T cells 
CD4 T cells are required for successful containment of M. tuberculosis infection.  Mice 
lacking CD4 T cells (CD4-/- or MHCII-/- mice) carry higher bacterial burdens and die 
significantly sooner than wild-type mice [103].  Chronically infected mice lose control of 
mycobacterial infection and succumb when CD4 T cells are depleted [104].  Humans and non-
human primates also require CD4 T cells for control of infection.  Co-infection with HIV (or SIV 
in the case of NHP) increases the risk of active TB and is associated with decreasing CD4 T cell 
numbers [105, 106].  When CD4 T cells are depleted in non-human primates during the initial 
stage of infection, macaques present with more disease by 8 weeks post-infection (p.i.).  
Depletion of CD4 T cells during latent infection in macaques causes reactivation of the infection 
in 50% of the animals (Lin, Flynn, unpublished).  Taken together, these studies underscore the 
importance of CD4 T cells in the immune response to M. tuberculosis infection. 
CD4 T cells develop in the thymus as either natural regulatory T cells (Tregs) [107] or 
naïve CD4 T cells (reviewed in [108]).  Naïve CD4 T cells can be primed to become one of three 
pro-inflammatory T-helper phenotypes: Th1, Th2 and Th17.  Each of these lineages is defined by 
a signature cytokine profile and requires a different series of cytokines present to activate lineage 
specific transcription factors (reviewed in [108]).  
Th1 CD4 T cells 
Th1 CD4 T cells are primed to produce IFN?, TNF, IL-2 and GMCSF [109].  Expression 
of these cytokines depends on the expression of IL-12 by DCs that act on the CD4 T cell to 
upregulate the transcription factor T-bet and signal through Stat-4 [110].  T-bet and Stat-4 
synergize to induce IFN?, and upregulate expression of IL-12r?2 and IL-18 receptor [111].  Thus 
enhancing the T cells ability to respond to pro-Th1 polarizing cytokines.  Interestingly, T-bet 
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knockout animals are more susceptible to M. tuberculosis infection than wild-type mice.  This 
vulnerability correlated to an increased production of the Th2 associated cytokine IL-10 and 
decreased IFN? production, underscoring the importance of the Th1 response to this infection 
[112].  In addition to promoting Th1 differentiation, T-bet blocks expression of Gata-3 (the 
transcription factor associated with Th2 differentiation) [113]. 
During the course of infection, naïve CD4 T cells encounter M. tuberculosis infected IL-
12 secreting DCs in the lymph node and recognize antigen in the context of MHC II.  Under 
these conditions, CD4 T cells are primed as Th1 cells and are a primary source of IFN? during 
the acute phase of the infection with peak production around 3-4 weeks p.i. in the murine model 
[114].  IFN? is required for control of M. tuberculosis infection.  Mice lacking IFN? are the most 
vulnerable strain, dying significantly earlier p.i. than any other immune compromised strain [77].  
In addition, humans with loss of function genetic mutations in IFN? signaling are more 
susceptible to mycobacterial infections (reviewed in [115]).  IFN? activates M?s to kill 
intracellular pathogens and increases the expression of MHC and co-stimulatory molecules on 
DCs [116].  IFN? enhances pro-inflammatory cytokine production in T cells and directly affects 
CD8 T cell expansion and differentiation into memory cells [117].  Mice lacking CD4 T cells 
exhibit a delay in IFN? production, but eventually reach levels equivalent to wild type, however 
this is insufficient to rescue the host [103].  When CD4 T cells were depleted from chronically 
infected mice, no change in IFN? levels in the lungs were observed [104].  These data indicate 
that during the course of the immune response to M. tuberculosis, cells other than CD4 T cells 
can and do produce IFN?.  This leads to the hypothesis that CD4 T cells have functions in 
addition to IFN? production (addressed in Chapter 3).   
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CD4 T cells influence the immune response to M. tuberculosis by the production of 
cytokines.  In addition to IFN?, Th1 CD4 T cells can produce TNF, IL-2, and GMCSF [118] 
(reviewed in [108]).  Production of IFN? and TNF by CD4 T cells activates M?s to induce 
bactericidal activity against intracellular pathogens [119] by inducing NOS2 to produce reactive 
nitrogen intermediates [120] and induction of the small GTPase LRG-47 [121].  Whereas IL-2 
directly impacts T cell expansion and survival [122], GMCSF has been shown to modify DC 
function improving IL-12 production and increasing expression of co-stimulatory molecules on 
the surface [123].  
CD4 T cells influence the quality of the CD8 T cell response. CD4 T cells interact with 
DCs to facilitate better antigen presentation and provide cytokines required for growth, survival 
and enhanced function.  In the absence of CD4 T cells, CD8 T cells can be primed, but are less 
cytotoxic [124].  Some data suggest this is due to the production of IL-2 by CD4 T cells [125].  
While CD4 T cells capable of secreting several cytokines simultaneously have been shown to be 
beneficial in other models of infection [126, 127], the correlation of protection in M. tuberculosis 
has yet to be established [128-130].  
Th2 CD4 T cells 
Th2 responses are essential for an effective immune response against extra cellular 
pathogens [131] and are also mediators of asthma (reviewed in [132]).  IL-4, IL-5 and IL-13 are 
the signature cytokines for Th2 CD4 T cells.  However it has been shown that Th2 CD4 T cells 
can also make TNF and IL-2, but in smaller quantities when compared to Th1 cells [133].  The 
transcription factor Gata-3 is the master regulator for Th2 differentiation [134] and promotes the 
priming of a Th2 response in the presence of both IL-2 and IL-4 [135].  Gata-3 promotes IL-4 
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production, instructing Th2 commitment, selectively promoting growth of Th2 cells while 
simultaneously suppressing Th1 differentiation [136].  
Th2 responses are not effective in response to M. tuberculosis.  M?s alternatively 
activated with IL-4 fail to kill intracellular bacteria [85].  Studies in the murine model of M. 
tuberculosis show that when mice are put under stress, they lose control of bacterial growth.  The 
increased bacterial growth is associated with a shift from Th1 type responses to Th2 type 
cytokine production [137].  In addition, humans with active disease have an increased production 
of IL-4 by CD4 T cells and CD8 T cells [138, 139] and increased Th2 type cytokine production 
was associated with the presence of cavitary lesions [138].   
Bacillus Calmette-Guerin (BCG) is an attenuated Mycobacterium bovis that has been 
used as a vaccine since 1921 with variable efficacy (0-80% protection depending upon the study) 
[140].  In areas endemic for helminth (worm) infection, the efficacy of BCG is greatly reduced 
[141].  This reduction is associated with a shift toward Th2 phenotype that is induced in people 
colonized with helminthes [142].  Subsequent studies in mice colonized with Schistosoma 
mansoni prior to BCG vaccination had reduced benefit from vaccination when challenged with 
virulent M. tuberculosis [143].  These data indicate that Th2 type responses cannot control M. 
tuberculosis infection and may abrogate an effective immune response against M. tuberculosis. 
Th17 CD4 T cells and other IL-17 producing cells  
IL-17 is a pro-inflammatory cytokine that recruits cells into parenchymal tissue, and is 
induced by IL-23 (reviewed in [144]).  The majority of IL-17 is produced by ?? T cells during 
the initial phases of M. tuberculosis infection [83].  However a small percentage of Th17 CD4+ 
T cells are primed to secrete this cytokine and thought to contribute to the recruitment of cells 
into the lung parenchyma [82, 145].  Interestingly, a decreased frequency of Th17 cells is 
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reported in patients with active TB, which was attributed to down regulation of the IL-6 receptor 
(the cytokine that in conjunction with IL-23 is needed to prime Th17 cells) [146].  However, it 
should be noted that IL-17 is not required for control of M. tuberculosis infection [82], at least in 
the murine model. 
CD4 Regulatory T cells 
CD4 T cells can also function as immune suppressive regulatory T cells (Tregs) and were 
first identified as potent inhibitors of autoimmunity [147].  Several different types of Tregs have 
been described within the literature.  Natural Tregs (nTregs) are thymically selected, express the 
IL-2 receptor ? chain (CD25) and the transcription factor Foxp3 [107, 148, 149].  Inducible 
Tregs (iTregs) have a phenotype similar to nTregs, but are induced from the naïve CD4+CD25- 
T cell population in the presence of T cell receptor (TCR) signal, IL-2 and TGF?1 [150-153].  In 
mice, iTregs have immunosuppressive activity, but in humans iTregs have not been 
demonstrated to have this function even when tested in vitro [154, 155].  Finally, two other types 
of Tregs are described in the literature as Tr1 and Th3 cells.  Both are defined by the cytokine 
produced with Tr1 secreting IL-10 and Th3 cells producing TGF?1 [156, 157].  While each of 
the Treg sub groups described here are referred to in the literature, their functions are not 
mutually exclusive since nTregs and iTregs have been reported to secrete IL-10 or TGF?1 to 
modulate the immune response.   
Both nTregs and iTregs require the transcription factor Foxp3 for suppressive activity 
[148, 158].  Scurfin-/- mice and humans with IPEX (immunodeficiency, polyendocrinopathy and 
enteropathy, X-linked syndrome) lack Foxp3, have no Tregs and present with multiple types of 
autoimmune responses [159, 160].  Furthermore, transduction of naïve CD4 T cells with a 
constitutively active Foxp3 induces a Treg phenotype capable of immunosuppression and similar 
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to nTregs [148].  TGF? is important for maintenance of nTregs [161].  TCR signaling in the 
presence of TGF? activates NFAT and Smad-3 which work in conjunction with Foxp3 to impart 
the immunosuppressive phenotype [162].  Regardless of origin, Tregs down-regulate the immune 
response by cell to cell contact and secretion of anti-inflammatory cytokines such as IL-10 and 
TGF? (reviewed in [163]).   
 Tregs have been shown to play a role in the establishment of persistent infections [164-
166].  Whether the presence of Tregs is beneficial or detrimental to the infection outcome 
remains controversial, and may be dependent on the pathogen and the stage of infection.  Tregs 
have been shown to facilitate immune evasion by Plasmodium spp. [166-168] and suppress HCV 
specific CD8 T cells [165, 169].  In contrast, in an experimental model of Leishmania major 
infection, Tregs facilitated pathogen persistence, however this was of benefit to the host because 
the presence of antigen was required for sustained immune protection [164].  The role of Tregs 
in M. tuberculosis infection is just as complex.  Multiple studies report Tregs are present in the 
lungs and lymph nodes of M. tuberculosis infected mice [170, 171].  Antigen specific Tregs 
expand first in the draining lymph node and then migrate to and accumulate at the site of 
infection [172].  These Tregs expand in response to the pro-inflammatory environment of the 
mycobacterial immune response [173].  However, whether Tregs are beneficial or detrimental to 
the host during M. tuberculosis infection has yet to be determined.  
To determine what role Tregs may contribute to the immune response to M. tuberculosis, 
initial studies in mice used antibody depletion of CD25+ T cells prior to M. tuberculosis 
infection.  Depletion of the nTreg population prior to infection had no effect on bacterial burden 
and disease course in the murine model, however it did result in increased IFN? production [174, 
175].  This approach was limited because CD25 is expressed on T cells as they become 
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activated, thus cells could be depleted only prior to infection and not continuously.  To overcome 
this issue, a bone marrow chimera model was used.  Mice received a mixture of bone marrow 
from scurfin-/- mice (Thy1.2+) and Thy1.1 wild type mice.  Thus, the bone marrow 
reconstitution provided a Treg population that was Thy1.1.  Tregs were depleted from the mice 
at different times post infection.  In this model depletion of Tregs resulted in a decreased but not 
eliminated bacterial burden.  Thus Tregs were found to limit antimycobacterial responses in the 
lungs [171].  Interestingly when lymphopenic mice were reconstituted with CD4 T cells only 
with and without CD4+CD25+ Treg population, mice lacking the initial Treg population had 
significantly less bacterial burden in the lungs or no culturable bacteria in the lung [176].  The 
reasons for this bimodal distribution remain unknown.  Finally, to determine whether Tregs were 
antigen specific and from which population (nTreg CD4+CD25+ or naïve CD4+CD25-) CD4 T 
cells transgenic for M. tuberculosis antigen 85A cells were used.  When adoptively transferred 
into Thy1.1 wild type mice, Tregs expanded first in the draining lymph node and migrated to the 
site of infection (i.e. the lung).  In addition these cells were antigen specific and expanded from 
the nTreg population [172].  Tregs may help M. tuberculosis establish a persistent infection or 
they may be acting to protect healthy tissue from immunopathologic damage.  (The role of Tregs 
in the murine model of M. tuberculosis infection is addressed more fully in chapters 4 and 5).   
Finally, Tregs may influence the development of active or latent infection in humans.  
Evaluation of persons with active disease showed an association between increased frequencies 
of Tregs in the peripheral blood when compared to healthy uninfected or latently infected 
controls [177-180].  Less antigen specific IFN? was produced by those with active disease, but 
was reversed when CD25+ Cells were depleted from the peripheral blood [177-181].  However, 
whether Tregs predispose an individual toward active disease or whether Tregs increase in 
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response to the inflammation associated with active disease is not understood (addressed in 
chapter 6).   
1.5.3.2 CD8 T cells 
CD8 T cells are primed in the lymph node, accumulate at the site of infection and appear 
to have a similar delay in priming in M. tuberculosis infection, as reported for CD4 T cells [96, 
182].  Functionally, CD8 T cells are primed to be either cytotoxic or secrete cytokines [183], 
with IFN? secreting CD8 T cells reportedly involved in control of bacilli during chronic infection 
[184].  CD8+ cytotoxic cells express perforin and have been shown to lyse infected macrophages 
[185].  While CD4 T cells are essential for an effective immune response to M. tuberculosis, the 
role of CD8 T cells has been harder to elucidate at least in the murine model of infection.  
However, the importance of CD8 T cells in TB was demonstrated in the NHP model, where 
antibody depletion of CD8 T cells results in loss of control of the mycobacterial infection (Lin, 
Flynn unpublished data).  CD8 depletion also impaired control of vaccine-induced immunity in a 
macaque model [186].  One hypothesis is that CD8 T cells eliminate cells that no longer respond 
to cytokines [187].  However, CD8 T cells can also produce cytokines such as IFN? and TNF 
and may contribute to M? activation [188].   
1.5.3.3 Other cells involved in the immune response 
In addition to T cells, other cell types are found within the granuloma such as B cells, ?? 
T cells, Natural killer (NK) cells, and NK T cells.  However the roles of these cells have not been 
as well defined as T cells. 
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B cells 
In addition to T cells, DCs and M?s, B cells are present within the granuloma, however 
their function are not as well understood as those of T cells in particular.  Studies in B cell 
deficient mice indicate that B cells may be acting as antigen presenting cells, and responsible for 
the generation of germinal centers within the infected lung [189-191].  In addition, several 
studies have suggested that B cells help to modulate the inflammation found at the infection site 
[191, 192].  
 In mice lacking B cells (μMT), infection with low dose aerosol M. tuberculosis resulted 
in increased inflammation and recruitment of neutrophils.  This was associated with an increased 
production of IL-10.  Furthermore, when infected with a higher dose, mice lacking B cells had an 
increased bacterial burden and susceptibility when compared to wild-type counterparts.  The 
increased susceptibility of B cell deficient mice infected with higher inoculum could be rescued 
by adoptive transfer of B cells prior to infection [191].  Thus B cells may contribute to the 
control of M. tuberculosis by modulating cytokine production at the site of infection.  
Traditionally, immune responses have been separated into humoral (antibody mediate) 
and cellular mediated immunity.  However, antibodies are able to modulate cellular mediated 
immunity through Fc? receptors (Fc?R).  Fc?Rs activate or inhibit the immune response 
depending on the threshold of activating or suppressing signals [193].  Activating Fc?Rs share a 
? chain that signals through an intracellular ITAM whereas the inhibiting receptor contains a 
cytoplasmic ITIM [193].  The balance between the two signals determines the amount of cellular 
activation [193].  When mice lacking the inhibitory receptor FC?RIIB were infected with M. 
tuberculosis, decreased bacterial burden and less immunopathology were observed at the site of 
infection.  Conversely, mice lacking the common ? chain (Fc?chain-/-), the loss of activating 
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signals resulted in an increased IL-10 production, increased bacterial burden, dissemination and 
susceptibility [194].  Taken together these studies indicate that B cells may play a role in 
modulating the immune response to M. tuberculosis by influencing both the cytokine 
environment and cellular activation state.   
1.5.4 Granuloma 
Initiation of the adaptive immune response results in CD4 T cells, CD8 T cells and B cells 
migrating from the draining lymph node to the site of infection and surrounding infected M?s 
and DCs.  Cell migration is mediated by various chemokines produced by infected cells and 
surrounding tissue [195, 196].  This discrete structure is called a granuloma.  It effectively walls 
off the bacteria that cannot be eliminated even in the presence of a robust Th1 response, thus 
benefiting the host [197].  The granuloma may also benefit the bacillus by providing a protected 
place for the mycobacteria to reside, in a non-replicative or occasionally replicating state for 
decades [198, 199].  Interestingly, bacterial components facilitate granuloma formation by 
interacting with M?s, DCs and lung epithelium to produce inflammatory chemokines [94, 200]. 
Granulomas in humans, NHPs, guinea pigs and rabbits are highly organized.  Infected 
M?s and DCs are surrounded by uninfected monocytes encased in a lymphocytic cuff.  In 
contrast, in mice the granulomatous structure appears as loosely organized aggregates of cells 
[37].  The phenotype of granulomas in humans and NHPs can range from a calcified (healing) 
granuloma to a necrotic cavitary lesion that can erode into the airways and cause spread of the 
bacilli [29].   
The granuloma serves as a barrier and is a dynamic interaction between the host immune 
response and the tubercule bacilli.  Fluctuation in factors that influence the immune response can 
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lead to loss of control of the bacilli and development of exacerbated disease.  Chemokines are 
required for granuloma formation and are induced by mycobacterial infection and by TNF.  
Depletion of TNF in mice, humans and NHP can result in loss of control of bacterial growth, and 
in primates, development of active disease [196, 201, 202].  Similarly, loss of T cells because of 
infection (HIV, SIV), immunosuppressive treatment [203] or due to antibody depletion can result 
in worsening infection [104, 106].   
 
 27 
2.0  STATEMENT OF THE PROBLEM 
Mycobacterium tuberculosis (M. tuberculosis) continues to be a threat to global public 
health because of a large potential reservoir of infection, lack of an effective vaccine to prevent 
infection or disease, and a long chemotherapeutic regime that is difficult to maintain.  Following 
infection, the host mounts a vigorous Th1 type immune response that contains, but does not 
eliminate the bacilli.  The hallmark of M. tuberculosis infection is the granuloma, a collection of 
immune cells that serves the host by walling off the bacteria, but also provides an environment in 
which the bacilli can persist insulated from the host.  Immunologic studies of M. tuberculosis 
infection have shown that an adaptive immune response is required for bacterial containment, of 
which CD4 T cells are an essential component.  In addition CD4 T cells can function to both 
promote and dampen inflammation.  The goal of this study was to examine the pro-inflammatory 
and regulatory role of CD4 T cells during the course of Mycobacterium tuberculosis infection.  
The murine model of M. tuberculosis, through the use of knockout and transgenic 
animals as well as antibody depletions, has been invaluable for discovering which components of 
the immune response are required for bacterial containment.  However the usefulness of this 
approach is limited to understanding the loss of function or gain of an immune component at a 
systemic level.  Thus one is not able to discern where and at what time these factors are critical.  
With the work presented in this dissertation, we developed a new model of adoptive transfer to 
address whether IFN? from sources other than CD4 T cells was sufficient to contain bacilli.  In 
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addition, we provide new insight into the role of regulatory T cells and the anti-inflammatory 
effects of long term IL-12 treatment in murine models.   
In humans, unlike mice, M. tuberculosis infection results in the development of either 
active disease or latent infection and the factors that contribute to such disparate disease 
outcomes are not well understood.  Most likely in humans, infection outcome is a spectrum 
between those with full-blown primary TB and those classified as having latent infection.  
Studies in humans suggested an association between an increased frequency of regulatory T cells 
(Tregs) and development of active disease.  Here I explored that association in a non-human 
primate model.  This is the only current animal model that mimics human active and latent M. 
tuberculosis infection.  We examine the association between Treg frequency prior to and during 
the first 6 months of infection in the blood and airways of M. tuberculosis infected cynomolgus 
macaques and infection outcome.  These studies address an important question in human TB: is 
control of initial infection dependent simply on a robust TH1 or inflammatory response, or is a 
more balanced immune response necessary for initial, and perhaps long term, containment of 
infection? 
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3.0  IFN?  FROM CD4 T CELLS IS REQUIRED FOR BACTERIAL CONTROL AND 
HOST SURVIVAL DURING ACUTE M. TUBERCULOSIS INFECTION  
3.1 INTRODUCTION 
The pro-inflammatory cytokine interferon ? (IFN?) promotes the development of a T-helper (Th) 
1 T cell response [204].  In addition, it synergizes with TNF? to activate macrophages (M?), 
promoting the induction of nitric oxide synthase (NOS2).  NOS2 produces nitric oxide that forms 
reactive nitrogen intermediates and in conjunction with reactive oxygen species can kill 
intracellular pathogens [205].  Humans with loss-of-function genetic mutations in either IFN? or 
its receptor are very susceptible to mycobacterial infections [115].  Mice lacking IFN? or NOS2 
are two of the most vulnerable strains, failing to control M. tuberculosis and succumbing within 
weeks of challenge [77, 206].  Thus, mice require NOS2 and IFN? and humans require IFN? for 
containment of M. tuberculosis infection and host survival. 
CD4 T cells are a primary source of IFN? during the adaptive immune response to M. 
tuberculosis infection and are required for host survival during both the acute and chronic stages 
of infection [103, 104].  CD4-/- and MHCII-/- mice are unable to control bacterial growth and 
succumb to infection significantly sooner than wild-type counterparts [103], yet these mice 
survive at least twice as long as those lacking IFN? or NOS2 [74, 77, 103, 206].  Lack of CD4 T 
cells during initial infection results in delayed IFN? and NOS2 production, but eventually levels 
 30 
comparable to wild type are reached, however this cannot rescue the mice from the infection 
[103].  When CD4 T cells are depleted during chronic infection, exponential bacterial growth 
and eventual host death occurs, despite maintenance of pre-depletion levels of IFN? and NOS2 
[104].  As Th1 cells, CD4 T cells also produce IL-2 and TNF, interact with dendritic cells to help 
with T cell priming and provide T cell help to B cells [108].  CD8 T cells as well as other cells 
can and do produce IFN? during M. tuberculosis infection.  Taken together, these data suggest 
that CD4 T cells may have roles in addition to IFN? production.  These data lead to the 
hypotheses that IFN? from sources other than CD4 T cells is sufficient for bacterial containment 
and CD4 T cells have functions in addition to IFN? production.  To test the hypotheses, an 
adoptive transfer model was designed to permit manipulation of the CD4 T cell population.  The 
adoptive transfer model was designed in two ways.  The first was a stream-lined model that 
specifically assessed the ability of CD8 T cells as a source of IFN? and second, a more 
comprehensive selection of the immune system components for reconstitution to assess the role 
of CD4 T cells in control of infection.   
The data from this study indicate that CD4 T cells are necessary as a source of IFN-?, as 
well as influencing the function of CD8 T cells in the immune response against M. tuberculosis.  
The adoptive transfer systems developed provide an opportunity to manipulate the immune 
response to identify specific factors important in control of M. tuberculosis infection. 
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3.2 MATERIALS AND METHODS 
3.2.1 Animals  
8-12 week old RAG1-/- (B6.129S7-Rag1
tm1Mom
/J), Thy1.1 (B6.PL-Thy1
a
/CyJ), IFN? -/- (GKO) 
(B6.129S7-Ifng
tm1Mom
/J), IFN?receptor-/- (B6.129S7-Ifngrtm1agt/J) and wild-type (WT) C57BL/6 
mice were obtained from Jackson laboratories (Bar Harbor, ME) or maintained in an in-house 
breeding facility.  Mice were maintained in a biosafety level 3 facility in micro-isolator cages, 
free fed a diet of mouse chow and autoclaved water.  All animals were maintained as per the 
University of Pittsburgh Institutional Animal Care and Use Committee.  
3.2.2 Probiotic pre-treatment of mice 
To prevent the development of reconstitution induced inflammatory bowel disease [207, 208], 
RAG 1-/- mice were prophylactically treated with probiotics.  Prior to adoptive transfer, mice 
received one scoop of Bene-Bac Powder (Pet Ag Inc. Hampshire, IL) (25 million Colony 
Forming Units (CFU) per gram, Lactobacillus fermentum, Enterococcus faecium, Lactobacillus 
plantarum, Lactobacillus acidophilus) in 350 ml of fresh, autoclaved water every day for 14 
days.  Water bottles were changed daily. 
3.2.3 Isolation of donor cells  
Thy1.1 mice were pretreated with 1mg/ mouse anti-CD4 antibody (clone GK1.5, NCCC, NIH 
Bethesda, MD) 7 days prior to splenocyte harvest.  GKO and WT mice did not receive 
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pretreatment with antibody.  Naïve donor mice were anaesthetized by isoflurane and euthanized 
by cervical dislocation.  Spleens were isolated under sterile conditions.  A single cell suspension 
was obtained by crushing each spleen individually through a 40μm cell strainer in Dulbecco’s 
phosphate buffered saline (Sigma-Aldrich, St. Louis, MO) with the back of a sterile 5ml syringe.  
Erythrocytes were lysed with red blood cell lysis buffer (90ml 0.16M NH4, 10ml 0.17M Tris pH 
7.65) for two minutes at room temperature.  Following erythrocyte lysis and wash, remaining 
splenocytes from like animals were combined.  Individual cell populations were isolated via 
Miltenyi MACS bead separation (Miltenyi Biotech, Auburn, CA) as per manufacture’s 
instructions.  For the first adoptive transfer model, CD8+ and B220+ cells were positively 
selected from Thy1.1 mice depleted of CD4+ cells.  In addition, CD4+ cells were positively 
selected from either WT or GKO mice.  For the second adoptive transfer model, naïve Thy1.1 
mice were depleted of CD4 T cells by antibody neutralization and then positive selection of CD4 
T cells by magnetic bead separation as per manufacturer’s protocol prior to adoptive transfer. 
3.2.4 Adoptive transfer to recipient mice 
Recipient RAG1-/- mice received purified splenocytes via a tail vein injection in 300μl of PBS 
per mouse. 
3.2.5 Aerosol infection of the mice 
M. tuberculosis was passed through mice, grown in culture once and frozen in 7H9 complete 
media 10% glycerol.  Immediately prior to infection, an aliquot was thawed and diluted in PBS 
0.05% Tween 80.  Bacteria were disaggregated by cup horn sonication.  Mice were aerosol 
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infected with low dose (<50 CFU, Erdman strain) using a nose-only exposure aerosolizer (InTox 
Products, Albuquerque, NM).  Mice were exposed to aerosolized M. tuberculosis for 20 minutes 
then room air for 5 minutes.  One day following infection, lungs of one mouse per round were 
crushed in 5 ml PBS-0.5% Tween-80 and plated neat on 7H10 or 7H11 plates (Difco 
Laboratories, Detroit, MI) to determine inoculum. 
3.2.6 Harvest of organs for analysis 
At serial time points following infection, mice were anesthetized with isoflurane and euthanized 
by cervical dislocation.  Under sterile conditions, organs were crushed in Dulbecco’s Modified 
Eagle Medium (Sigma-Aldrich) through a 40μm cell strainer with the plunger from a sterile 5ml 
syringe.  An aliquot of cellular homogenate was plated on 7H10 agar plates for CFU 
determination.  Cells were then pelleted and washed.  Erythrocytes were lysed as described 
previously and cells were resuspended for enumeration and assay set up. 
3.2.7 Flow cytometry 
For intracellular cytokine staining, cells were stimulated with media only or with anti-CD3 
(10μg/ml, clone 145-2C11, BD Pharmingen) and anti-CD28 (10μg/ml, clone, BD Pharmingen) 
and monensin (3μM, for 5 hours at 37°C 5% CO2) (Sigma-Aldrich).  For antigen specific 
responses, cells were incubate with 1μl of either ESAT61-20aa MHC Class II multimer or GAP 
MHC Class I tetramer (Mtb32aa309-318 (GAPINSATAM) NIAID tetramer facility, Bethesda, MD) 
per 100μl at 37°C 5%CO2 for 60 minutes in media then washed.  Once stained with tetramers, 
cells were stimulated with either ESAT61-20aa peptide or GAP peptide in the presence of 
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monensin for 5 hours.  During staining with GAP tetramer, anti-CD107 (1D4B, BD Pharmingen) 
antibody was present during the stimulation period to assess degranulation.  Following 
stimulation, cells were surfaced stained for CD3, CD4 (clone L3T4, BD Pharmingen), and CD8 
(clone 53-6.7, BD Pharmingen) at room temperature for 15 minutes in PBS 0.5% BSA 20% 
Mouse serum, washed and then fixed with 2% paraformaldehyde (Sigma-Aldrich) for one hour.  
Following fixation, cells were permeablized then washed with PBS 0.5% BSA 0.2% Saponin  
(Sigma-Aldrich).  Cells were stained for intracellular cytokines IFN? (clone XMG-6.1, BD 
Pharmingen) and TNF (clone MP6-XTT22, BD Pharmingen) by incubating antibodies in PBS 
0.5% BSA 0.2% Saponin and 20% mouse serum for 15 minutes at room temperature.  Cells were 
washed and resuspended in 1% BSA.  Data were collected on a FACS Aria and analyzed using 
FloJo software 8.6.3 (Treestar).   
3.2.8 RNA Isolation 
At the time of harvest, a lobe of lung was isolated under sterile conditions and immediately flash 
frozen in liquid nitrogen in an RNAse free, sterile cryovial, and stored at -80°C until RNA 
harvest.  For RNA isolation, frozen tissue was homogenized in TRIzol reagent protocol with 
modifications.  Tissue was homogenized using a dounce homogenizer in 3ml of TRIzol and 
extracted with chloroform twice.  RNA was precipitated with isopropanol and washed with 70% 
Ethanol.  RNA was further purified on an RNAeasy Mini Kit column (Qiagen ). 
 35 
3.2.9 Real time quantitative PCR 
As reported previously, the RNA was reversed transcribed by Superscript II enzyme as per 
manufacturer’s instructions (Invitrogen, Carlsbad, CA)[201].  The relative gene expression 
method was used to report the data.  Data were normalized to hypoxanthine 
phosphoribosyltransferase with uninfected lung as a calibrator.  Primer probe sets were tested for 
efficiency with efficiency >97% for all sets.  Triplicates of each sample were run along with a no 
RT control on an ABI PRISM Sequence Detector 7700.  Data are reported as relative gene 
expression to uninfected samples.  To calculate the relative gene expression (2
(-?? cycle threshold (Ct))), 
?Ct=Ct (Gene of interest)-Ct(normalizer) and the ??Ct= ?Ct (sample)- ?Ct (calibrator). 
3.2.10 Macrophage killing assay 
Bone marrow derived macrophages were obtained by culturing bone marrow from the long 
bones of mice with 25% L929-cell supernatant containing media for 5 days in 10cm culture 
dishes (2.5x10
6
 cells/ plate in 10 ml media).  Cells by this time had formed a monolayer of 
macrophages.  Macrophages were removed by incubation with PBS on ice for 20 minutes 
followed by vigorous pipetting to dislodge any remaining adherent cells.  Once removed, the 
cells were pelleted, resuspended, counted and diluted to a concentration of 2.5x10
7
 cells/ml with 
macrophage infection media (DMEM, 1% FBS, 1% sodium pyruvate, 1% L-glutamine, 1% non-
essential amino acids).  Macrophages were plated at 100μl/well in a 96 well plate and allowed to 
adhere for 45 minutes.  Subsequently, macrophages were infected with M. tuberculosis at an 
MOI?1 for 4 hours at 37°C 5% CO2.  After the macrophage infection, supernatant from three 
wells per macrophage type was saved and the macrophages in all wells washed.  Three wells per 
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each macrophage type were lysed with 1% Saponin and the saved supernatant and macrophage 
lysis were diluted and plated on 7H10 plates to determine the “input” bacterial numbers.   
T cells from the lungs of wild type mice infected with M. tuberculosis for 4 weeks 
Infected mice were anesthetized with isoflurane and euthanized by cervical dislocation.  Lungs 
were retrieved under sterile conditions and crushed through a 40μm cell strainer with the back of 
a sterile 5 ml syringe.  Once a single cell suspension was obtained and erythrocytes lysed, CD4 
and CD8 T cells were purified by magnetic bead separation (Miltenyi) as per manufacturer’s 
instructions.  T cells were incubated in wells with infected macrophages at a 1:1 ratio of T cell to 
macrophage (n=3 wells per condition) Media without T cells in wells with infected macrophages 
was used as a control for growth of M. tuberculosis.  As a positive control, wells were treated 
with IFN? (250U/ml, Invitrogen) and LPS (3μg/ml, Sigma-Aldrich).  Cells were incubated for 72 
hours at 37°C 5% CO2.  Following incubation, supernatant was removed and saved and cells 
were lysed with 1% Saponin.  Supernatants and cell lysates were serially diluted and plated on 
7H10 agar plates for determination of bacterial burden per well.   
3.3 RESULTS 
3.3.1 Building the adoptive transfer model 
Knockout and transgenic animals as well as antibody depletion have been powerful tools for 
determining which factors are necessary for control of M. tuberculosis.  However, these 
techniques are limited by studying the global effect of the factors, and it can be difficult to 
determine which specific function of a cell type, for example, is causing the in vivo phenotype in 
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a murine model.  To determine whether IFN? from sources other than CD4 T cells were 
sufficient to contain bacterial growth, a new model system was needed.  An adoptive transfer 
model was developed so that the presence or absence of CD4 T cells from IFN-g-/- or wild type 
(WT) mice could be compared for ability to control M. tuberculosis infection.  Three 
experimental groups were needed: 1) a control group lacking CD4 T cells (CTLAT), 2) a group 
in which CD4 T cells were from IFN?-/- mice (?AT) and 3) a group in which CD4 T cells were 
from WT mice (WTAT).  In addition, the remainder of the immune system components had to be 
capable of producing IFN?.   
Several initial attempts to adoptively transfer CD4 T cells into CD4 deficient mice were 
not successful.  Adoptively transferred cells were often hard to find and did not remain within 
the host (data not shown).  In addition, CD4-/- mice have been reported to have double negative, 
MHCII restricted T cells that are able to respond in certain infection models [209].  Thus, RAG 1 
deficient mice were chosen as recipients.  RAG 1-/- mice lack B cells and T cells, but approach 
wild-type levels of innate immune responders, yet do not produce excessive amount of IFN?, as 
has been reported in other immune compromised strains [210].  
The development of this model was approached in two distinct ways. The first was a 
streamlined model in which CD8 T cells and B cells from Thy 1.1 congenic mice were 
adoptively transferred with or without CD4 T cells from WT or IFN?-/- mice (both of which had 
the Thy1.2 marker) at a ratio of 4:1 (CD8 T cells and B cells to CD4 T cells) (Figure 1A).  The 
second approach was to create a more natural context for immune response with the hope of 
extending the length of time infection could be sustained.  For this, we reconstituted RAG1-/- 
mice with and without CD4 T cells from WT or IFN? mice in conjunction with whole spleen 
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equivalents.  The whole spleen equivalents were derived from CD4-depleted naïve Thy1.1 mice 
and adoptively transferred at a ration of 20:1 (CD4- splenocytes to CD4 T cells).  (Figure 1B).  
In addition to varying the type and number of cells used to reconstitute the recipients, we 
also experimented with the length of time between reconstitution and M. tuberculosis infection.  
Initially, animals were reconstituted one day prior to infection.  However, the responses to 
infection, primarily cytokine production, were extremely vigorous.  A majority of cells 
examined, when stimulated with anti-CD3 and anti-CD28, produced large amounts of IL-2, TNF 
and where applicable IFN?.  We hypothesized that one possible cause of the exacerbated 
cytokine production was the homeostatic proliferation that occurs when RAG 1-/- mice are 
reconstituted with lymphocytes [211].  By extending the time between reconstitution and 
infection from one day to 18 days, the model better approximated the conditions found in wild 
type mice.  
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A.  Stream-lined Model 1
CD4           CD8          B cell
------        Thy1.1        Thy 1.1
IFNg-/-    Thy 1.1       Thy 1.1
WT       Thy 1.1       Thy 1.1
CTLAT
GammaAT
WTAT
RAG 1-/-
CTLAT
GammaAT
WTAT
RAG 1-/- CD4       Spleen eq
-----          Thy1.1
IFNg-/-      Thy1.1
WT          Thy1.1
B.   Splenic equivalent Model 2
C.  Experimental Time line
2wk 4wk 6wk-4wk -2.5wk day 0
M. tb infection
8GammaRAT
CD8
IFNgR-/-    Thy 1.1
Probiotic Rx Reconstitution
Adoptive 
Transfer  
Figure 1 Design of adoptive transfer models and time line for set up. 
Two models of adoptive transfer are described here.  A) the streamlined model in which only B cells; CD4 and CD8 
T cells were transferred into RAG1-/- mice.  B) reconstitution with CD4 depleted splenic equivalents. C) the time 
line of experimental setup. 
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3.3.2 IFN?  from CD8 T cells is not sufficient to control M. tuberculosis infection in the 
absence of IFN?  from CD4 T cells 
3.3.2.1 IFN?  from CD4 T cells is required for host survival 
To determine whether IFN? from non-CD4 T cell sources was sufficient for host survival, the 
first adoptive transfer model shown in Figure 1A was used.  Five groups of mice were infected 
with an n=5 mice per group:  wild type (WT), RAG1-/- that did not receive lymphocytes, 
CTLAT (received only CD8 T cells and B cells), ?AT (received CD4 T cells from IFN?-/- mice) 
and WTAT (received CD4 T cells from WT mice).  Following infection, mice lacking IFN? from 
CD4 T cells failed to survive longer than non-reconstituted RAG 1-/- mice, while 80% of mice 
reconstituted with CD4 T cells from wild type mice survived until the end of the experiment 
(Figure 2). This indicated that IFN? from CD4 T cells is essential for host survival. 
 
 
 
 
 
 
 
 
Figure 2 Murine survival after adoptive transfer and subsequent M. tuberculosis infection  
RAG1-/- mice were adoptively transferred with CD8 T cells and B cells from naïve Thy 1.1 mice in the presence 
and absence (CTLAT) of CD4 T cells from either IFN? -/- (?AT) or wild type (WTAT) mice.  As controls, a group 
of RAG1-/- mice were sham reconstituted with PBS.  (n=5 per group). 
Survival proportions
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3.3.2.2 In the absence of CD4 T cells that produce IFN? , bacterial growth is unchecked 
Given that lack of IFN? from CD4 T cells was necessary for survival of the host, it was not 
surprising to find that the bacterial burden in lungs was significantly higher in animals that had 
not received CD4 T cells or had received IFN?-/- CD4 T cells by 4 weeks post infection (Figure 
3A).   
3.3.2.3 CD4 T cells are required for an effective immune response 
In general, as antigenic burden increases one expects a proportional increase in the number of 
cells at the site of infection [97].  However, in the absence of CD4 T cells, almost no cells were 
recovered in the lungs of CTLAT animals until 6 weeks post infection.  In contrast, animals that 
received CD4 T cells, even in the absence of CD4-derived IFN?, had an increase in the number 
of cells in the lung as the bacterial burden increased over time, indicating that CD4 T cells are 
necessary for either induction or maintenance of the immune response and this is independent of 
IFN? production (Figure 3B) 
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Figure 3 Bacterial burden and cellular infiltrate in the lungs of experimental animals over time 
Lungs of experimental animals were harvested at serial time points post infection and homogenized.  An aliquot of 
organ homogenate was serially diluted and plated on 7H10 agar plates for enumeration.  Following crushing, 
erythrocytes were lysed and the remaining cells counted by trypan blue exclusion.  Statistical significance was 
determined by ANOVA analysis and a p<0.05 considered statistically significant. At 4 weeks post infection in A, 
p<0.05 for ?AT and CTLAT when compared to WTAT and wild type and p<0.05 for ?AT CTLAT and WTAT when 
compared to WT at 6 weeks post infection.  In B p<0.05 for ?AT when compared to CTLAT at 4 weeks and 
compared to all other groups at week 6 p.i. 
3.3.2.4 In the absence of CD4 T cells, CD8 T cells are activated, but fewer are present in the 
lungs. 
Analysis of lymphocytes recovered from the lung showed that, as expected, CTLAT mice lacked 
CD4 T cells, while ?AT and WTAT mice had comparable frequencies of CD4 T cells (Figure 
4A).  When CD4 T cells were not present, the frequency of CD8 T cells found within the lung 
was significantly lower compared to experimental groups that had received CD4 T cells (CTLAT 
vs. WTAT or ?AT, Figure 4B).  However, it is interesting to note that while the CD8 T cell 
frequency was lower, the activation profile of the cells present was comparable in all groups 
(Figure 4D).  Taken together, these data suggest that CD4 T cells, independent of IFN? 
production, provide help for CD8 T cell expansion or survival during M. tuberculosis infection.  
In addition, the presence of CD4 T cells does not seem to affect whether the CD8 T cells are 
activated or not. 
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Figure 4. The frequency and activation status of T cells within the lung 
To determine the frequency of each cell type present in the lung, cells were surface stained with CD3, CD4, CD8 
and CD69 as previously described.  The data are reported as a frequency of CD4 T cells (A) and CD8 T cells (B) 
within the lymphocyte gate.  The activation state of the CD4 (C) and CD8 (D) T cell populations are reported as the 
percent CD69+ within each population.  Overall statistical significance was determined by ANOVA, while 
significance between pairs was determined by bonferroni and a p<0.05 was considered statistically significant.  In A, 
p<0.05 for CTLAT when compared to both ?AT and WTAT at 2 and 4 weeks p.i. where as in C the p<0.05 for 
CTLAT compared to the other experimental groups for all three time points.  Finally, P<0.05 between WTAT and 
CTLAT at 2 weeks and between CTLAT and the other two groups at week 4 in B. 
3.3.2.5  Adoptively transferred CD4 T cells produce pro-inflammatory cytokines 
In wild type mice, as Th1 cells, CD4 T cells produce pro-inflammatory cytokines during the 
course of M. tuberculosis infection.  To determine whether adoptively transferred CD4 T cells 
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were capable of producing pro-inflammatory cytokines, cells isolated from lungs of infected 
animals were stimulated and then stained for intracellular cytokines.  As expected CD4 T cells 
from WTAT animals produced IFN? while those from ?AT did not (Figure 5A) while CD4 T 
cells from both groups produced TNF (Figure 5B). 
3.3.2.6 The quality of the CD8 T cell function is altered in the absence of IFN?  from CD4 T 
cells 
Studies of M. tuberculosis infection in CD4-/- and MHCII-/- mice have shown that a CD8 T cells 
can be a significant source of IFN? [103, 124].  In the adoptive transfer model, we sought to 
determine the quality of the CD8 T cell response generated.  Animals lacking CD4 T cells had a 
reduced frequency of CD8 T cells that produced either IFN? (Figure 5C) or TNF (Figure 5D).  
Interestingly, when CD4 T cells could not make IFN?, the frequency of CD8 T cells capable of 
producing cytokine was reduced by approximately 20% at the peak of the infection (4 wks).  
These data indicate that CD4 T cells are required for a quality CD8 T cell response and that IFN? 
from CD4 T cells may act directly on CD8 T cells to boost the frequency of cells capable of 
producing cytokine. 
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Figure 5. Cytokine production by T cells 
Cells isolated from the lungs of experimental animals and stimulated with anti-CD3 and anti-CD28 in the presence 
of monensin for 5 hours at 37°C 5% CO2.  Following stimulation, the cells were surface stained for CD3, CD4, CD8 
and intracellularly stained for IFN? and TNF.  The frequency of CD4+IFN?+ (A), CD4+TNF+ (B), CD8+IFN?+(C) 
and CD8+TNF+(D) cells are reported as a percent of their T cell population.  Statistical significance was determined 
by ANOVA and a p<0.05 was considered statistically significant.  Significance between pairs was determined by a 
bonferroni posttest when ANOVA was statistically significant.  In all the above figures, p<0.05 was between WTAT 
and CTLAT values at all time points.  
3.3.2.7 IL-2 from CD4 T cells may account for the poor immune response in animals 
lacking CD4 T cells. 
As helper cells, CD4 T cells produce IL-2 during the course of an immune response.  However 
CD8 T cells are able to make IL-2 as well.  To address whether the poor immune response seen 
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in mice lacking CD4 T cells may be due to a lack of IL-2, we performed quantitative REAL-
Time PCR on RNA from the lungs of adoptively transferred and infected mice.  Mice lacking 
CD4 T cells had no IL-2 gene expression (Figure 6) indicating that lack of IL-2 may be 
responsible for the poor immune response. 
 
 
 
 
  
 
 
Figure 6. IL-2 expression in the lungs of reconstituted mice 
At the time of necropsy, a lobe of lung was taken and flash frozen in liquid nitrogen for RNA isolation and analysis 
of IL-2 expression over time. 
3.3.3 IFN?  from CD4 T cells is necessary for antigen specific responses and directly 
affects the quality of the CD8 T cell response 
The “stream-lined” adoptive transfer model evaluated whether IFN? from CD8 T cells was 
sufficient in the absence of IFN? from CD4 T cells. In this model, CD4 T cells were a necessary 
source of IFN? to control M. tuberculosis infection. However, T cells are not the sole immune 
cells capable of producing IFN?, therefore the model was further developed to approximate a 
more wild type immune system.  Using half splenic equivalents in which naïve splenocytes were 
depleted of CD4 T cells and adoptively transferred into RAG1-/- mice with and without isolated 
IL-2 expression over time
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naïve CD4 T cells from IFN?-/- or WT mice.  An additional experimental group was added to 
evaluate the direct effects of IFN? signaling CD8 T cells.  This group of RAG1-/- mice (8?rAT) 
was reconstituted with CD8-depleted splenic equivalents and CD8 T cells from IFN? receptor -/- 
mice were added back (Figure 1B). With the use of tetramers, we were able to determine whether 
the deficits in the response on a global T cell scale were also happening at an antigen specific 
level.   
3.3.3.1 IFN?  from CD4 T cells is required for control of bacterial burden 
Even when other components of the immune system capable of producing IFN? are 
present, experimental animals lacking IFN? from CD4 T cells fail to contain bacterial growth 
(Figure 7A).  The CTLAT group, which lack CD4 T cells completely, had the highest bacterial 
burden, however the increased bacterial burden differs only slightly from the groups that have 
CD4 T cells. This is different than the bacterial burden of mice adoptively transferred without 
splenic equivalents (i.e. the first adoptive transfer model described).  
3.3.3.2  Without CD4 T cells, fewer cells are found at the site of infection 
Similar to previous results, the group lacking CD4 T cells had 4 fold fewer cells found in 
the lungs during the first weeks post infection (Figure 7 B), indicating that CD4 T cells are 
needed to initiate or sustain an adaptive immune response to M. tuberculosis.  
3.3.3.3 Antigen specific CD4 and CD8 T cells can be detected in the lungs of experimental 
animals. 
Over the course of infection, CD4 T cells continue to expand within experimental groups 
(Figure. 7C) whereas CD8 T cells peak in the lungs at week 2.5 post infection in all experimental 
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groups (Figure. 7E).  Using tetramers to track antigen specific cells, CD4+ ESAT-6+ (Figure 7D) 
and CD8+GAP+ (Figure 7E) T cells were found within the lungs of infected animals.   
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Figure 7. Bacterial burden, total cell numbers and T cells in an adoptive transfer model using whole 
spleen equivalents 
Using a more physiologic mix of cells, RAG1-/- mice received CD4 depleted naïve Thy1.1 half spleen equivalents 
in the presence of absence of CD4 T cells from IFN?-/- or WT mice (n=4 mice per group per time point).  One 
additional group received CD8 depleted half spleen equivalent and CD8 T cells from IFN? receptor -/- mice.  
Bacterial load was determined by plating serial dilution of organ homogenates on 7H10 agar plates (A).  The total 
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number of cells per lung (B) was determined by trypan blue exclusion.  The frequency of CD4 T cells within the 
lymphocyte gate (C), CD4+ESAT6tet+ cells within the CD4 T cell gate (D), of CD8 T cells within the lymphocyte 
gate (E) and the frequency of CD8+GAPtet+ cells within the CD8 gate (F) were determined by flow cytometry. 
3.3.3.4  Cytokine production by antigen specific CD4 T cells 
During the course of infection we sought to determine whether CD4 T cells produced 
cytokine in response to antigen-specific stimulation.  CD4 T cells from the lungs were stained 
with ESAT-6 tetramer and stimulated with ESAT61-20aa peptide in the presence of monensin.  
Interestingly, in groups that received CD4 T cells capable of producing IFN?, a delay was 
detected until approximately 5.5 weeks post infection within the tetramer positive population 
(Figure 8A).  In contrast, both TNF (Figure 8B) and IL-2 (Figure 8C) were produced at even the 
earliest time point.  These data indicate that at least within this population, CD4 T cells are 
functional and producing cytokine.   
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Figure 8. Antigen specific cytokine production by CD4 T cells 
Lung cells were stained with ESAT6 tetramer and subsequently stimulated with ESAT61-20aa peptide in the presence 
of monensin.  Following stimulation, cells were stained for surface markers and intracellular cytokines. 
3.3.3.5 Antigen specific CD8 T cell functions 
In the previously described experiment using only CD4 T cells, CD8 T cells and B cells, 
we described attenuated CD8 T cell response in the absence of CD4 T cells and a slightly 
truncated production of cytokines in groups lacking IFN? from CD4 T cells.  In these 
experiments, we sought to determine whether lack of IFN? directly affects CD8 T cells.  To do 
this an additional experimental group was added, where Thy 1.1 splenocytes depleted of CD8 T 
cells and CD8 T cells from IFN? receptor deficient mice were used to reconstitute the animals.  
First, we wanted to determine whether IFN? directly affected cytotoxic CD8 T cells by using 
CD107 staining as a measure of exocytosis/ degranulation.  To follow M. tuberculosis specific 
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responses, we followed the CD8 T cell responses using tetramer techonology.  GAPtet is a 
fluoroflor linked MHC I molecule that holds the peptide GAPINSATAM. Interestingly it 
appeared that neither lack of CD4 T cells nor the inability to respond to IFN? played a role in the 
development of the ability of the CD8+GAPtet+ cells to degranulate (Figure 9A).  This is in 
contrast to previous work in the CD4-/- mouse that showed lack of CD4 T cells resulted in a 
decreased cytotoxic precursor frequency [124].  This may be explained by the differences in 
cytotoxic T cell detection, i.e. limited dilution assay versus flow cytometry.  Lack of CD4 T cells 
or IFN? signal did not significantly affect IL-2 production within this cell population (Figure 
9B).  However, at 4.5 weeks post infection, lack of IFN? signal for CD8 T cells resulted in 
slightly fewer cells producing TNF (Figure 9C) and significantly fewer CD8 T cells producing 
IFN? (Figure 9D).  The reduction seen at this time point is similar to the reduction reported at the 
peak of infection in our other model of adoptive transfer. Taken together these data suggest that 
at the peak of the inflammatory response (~4-5 weeks p.i.) IFN? from CD4 T cells directly 
enhances the CD8 T cells production of both TNF and IFN?.   
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Figure 9. Antigen specific CD8 T cell function 
Cells from the lungs of M. tuberculosis infected animals were stained with GAP tetramer and stimulated with GAP 
peptide in the presence of monensin and CD107.  Following stimulation cells were stained for surface markers and 
intracellular cytokines.  Cells are gated on live cell gate, lymphocyte gate, CD8 and finally GAPtet.  Data was 
analyzed by flow cytometry and reported as a frequency of the CD8+GAPtet+ population. Statistical significance 
was determined by analysis of variance and a p<0.05 considered statistically significant. 
3.3.3.6  The effects of whole spleen equivalents on host survival 
In experiments using our first model of adoptive transfer, mice lacking CD4 T cell and 
mice that had received IFN?-/- CD4 T cells failed to control bacterial burden and succumbed to 
infection as quickly as RAG1-/- mice that had not been reconstituted.  In addition, the mice in 
both groups had exponentially higher bacterial burdens by 4 weeks post infection.  Interestingly, 
when bacterial burden was assessed using the second model of adoptive transfer using splenic 
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equivalents to reconstitute, mice that received IFN?-/- CD4 T cells had bacterial burdens in the 
lungs that were similar to those mice that had received wild type CD4 T cells.  In a subsequent 
experiment, we sought to determine whether the presence of other cell types in these adoptive 
transfer mice were able to increase survival in mice with or without CD4 T cells.  Interestingly, 
the group lacking CD4 T cells succumbed to infection just as quickly as previously reported.  
However, mice with IFN?-/- CD4 T cells survived twice as long (Figure 10).  In addition, at the 
time of death, mice lacking CD4 T cells carried a 1000-fold higher bacterial burden (average log 
CFU 9.7+0.1 SEM) than did those with CD4 T cells  (day 78p.i. ?AT log CFU 6.5+0.01 SEM, 
WTAT log CFU 6.0+0.18 SEM).  These data indicate that CD4 T cells in the presence of whole 
spleen equivalents were able to extend the life of M.tuberculosis infected mice, suggesting that 
CD4 T cells have integral functions in addition to IFN? production during the early stages of 
infection. 
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Figure 10. Survival of mice reconstituted +/- CD4 T cells and splenic equivalents 
RAG1-/- mice were reconstituted as previously described (adoptive transfer model 2) and infected with low dose M. 
tuberculosis to assess survival. (n=5 mice per group). 
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3.3.4 T cell activation of macrophages to kill intracellular bacilli in the presence or 
absence of IFN?  
T cells that produce IFN? are capable of interacting with macrophages, via cytokine production 
(i.e. IFN?) and cell-to-cell contact.  IFN? can synergize with TNF to activate the macrophage and 
mobilize mechanisms of intracellular killing.  We sought to determine whether T cell-
macrophage interactions were sufficient in the absence of IFN? signal to activate the macrophage 
to kill intracellular M. tuberculosis.  We hypothesized that one of three possible outcomes were 
possible in the absence of IFN? signal between macrophage and T cell (Figure 11A):  1) Cell-to-
cell contact would be sufficient to activate bactericidal activity, 2) in the absence of IFN? signal, 
bacterial growth would be limited (bacteriostatic), or 3) T cells would fail to slow intracellular 
bacterial growth.  To test our hypothesis, we utilized the macrophage killing assay.  Bone 
marrow derived macrophages from either wild type or IFN? receptor-/- mice were infected with 
M. tuberculosis and incubated with media only, LPS/IFN?, CD4 T cells or CD8 T cells isolated 
from the lungs of M. tuberculosis infected wild type mice for 72 hours.  Following incubation, 
the bacterial burden per well was calculated and compared to the initial input.  Wild type T cells 
(either CD4 or CD8 T cells) were able to activate macrophage killing of intracellular bacteria 
when macrophages were from WT mice (Figure 11B).  Interestingly in the absence of IFN? 
signal, T cells were able to limit bacterial growth, but not induce bactericidal macrophage 
activity (Figure 11C).  
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Figure 11. Macrophage killing assay 
Bone marrow derived macrophages were infected with M. tuberculosis, incubated with T cells isolated from the 
lungs of wild type M. tuberculosis infected mice and evaluated for the ability to kill intracellular bacilli after 72 
hours of incubation. 
3.4 DISCUSSION 
IFN? and NOS2 are required for control of mycobacterial infections [77, 115, 206].  CD4 T cells 
are a primary source of IFN? during the initial phases of M. tuberculosis infection.  Literature 
reports of studies in knockout mice and antibody depletions have shown that CD4 T cells are 
required for an effective response against M. tuberculosis [103, 104].  In addition, they provided 
valuable insight as to the functions CD4 T cells may have in addition to IFN? production.  
However, the traditional approaches of knockout and transgenic mice, as well as antibody 
mediated depletion, only provide information about the global effects of loss or gain of the CD4 
T cell subset and fail to evaluate the source of these factors.  With data presented in this chapter, 
we sought to investigate the role of IFN? from CD4 T cells during M. tuberculosis infection.  To 
do that, I developed two models of adoptive transfer.  First, we used a more stream-lined model 
that allowed us to specifically evaluate whether CD8 T cells were a sufficient source of IFN? 
when CD4 T cells were present, but unable to make IFN?. The second model utilized a plethora 
of splenocyte cell types and permitted us to evaluate if in a more physiologic environment 
whether the lack of IFN? from CD4 T cells could be overcome and host survival and bacterial 
burden contained.   
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In both experimental adoptive transfer models, the data indicate that CD4 T cells are 
essential for the control of M. tuberculosis infection and host survival since both groups lacking 
CD4 T cells failed to live longer than RAG1-/- mice that had not received CD4 T cells.  These 
data agree with published literature from both knockout and antibody depletion studies.  In 
addition, mice reconstituted without CD4 T cells had a truncated or abortive immune response in 
which higher bacterial burden failed to elicit an expected dramatic increase in cellular infiltrate.  
This may be because CD4 T cells are the initial and primary source of IL-2 as was demonstrated 
by the lack of IL-2 measured by real-time quantitative PCR.  An additional explanation, untested 
in these experiments, is that in the absence of CD4 T help, dendritic cells do not receive the 
proper signals to activate the available T cells.  
These experiments showed that CD8 T cells in the presence of only B cells and CD4 T 
cells are not a sufficient source of IFN? for bacterial control or host survival.  Interestingly, when 
an entire splenic complement of cells was provided in the presence of CD4 T cells that didn’t 
produce IFN?, animals were able to better able to control bacterial and survive twice as long as 
animals that did not have CD4 T cells.  These data indicate that cell types other than CD4 T cells 
are capable of producing enough IFN? to initially stunt growth of the bacteria, but long term, 
IFN? from CD4 T cells is necessary survival. 
We showed that independent of IFN? production, CD4 T cells are required for an 
appropriate activation and cellular infiltrate into the site of infection.  However, IFN? is required 
for maximal quality CD8 T cell cytokine production, but not necessarily for a cytotoxic T cell 
response.  These data differ from studies completed in CD4 deficient mice that reported lack of 
CD4 T cells resulted in a defect in cytotoxic T cell precursors [124].  The disparity in these 
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results may be due to the methods of measuring the frequency of cytotoxic T cells, here by flow 
cytometry and in literature by limiting dilution assay.  
Finally, we evaluated the ability of CD4 T cells and CD8 T cells from the lungs of 
infected mice to activate macrophages and kill intracellular pathogens in the presence and 
absence of an IFN? signal.  Here the data indicate that IFN? signal is required for bactericidal 
activity in macrophages.  This was expected as the literature reports that NOS2 and LRG47 (both 
induced by IFN?) are required for mycobactericidal macrophage activity.  Surprisingly, T cells 
were able to halt growth of intracellular bacilli, but not kill the bacteria, which leads naturally to 
questions of mechanism that are a focus of subsequent future studies.  
With the development of this adoptive transfer model, we’ve provided a basis upon 
which we can begin to ask questions about the specific origin and function of cytokines from 
particular sources.  It provides a powerful tool to move beyond global systemic neutralization or 
loss of function and begin to discover when and from where the factors required for an effective 
immune response against M. tuberculosis originate. 
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4.0  DELETION OF CD4+CD25+ REGULATORY T CELLS PRIOR TO M. 
TUBERCULOSIS INFECTION DOES NOT CHANGE INFECTION OUTCOME 
4.1 INTRODUCTION 
When controlled, M. tuberculosis infection results in discrete areas of organized immune 
cells called granulomas that contain the bacteria, yet do not affect surrounding areas of healthy 
tissue. In order to contain the bacilli a robust Th1 response is required.  To maintain the integrity 
of the healthy tissue, presumably the Th1 response must be limited to the areas of infection-
involved tissue, and that likely requires factors that balance the inflammation caused by Th1 
responses.  The factors that contribute to the regulation of the immune response are largely 
unknown.  One hypothesis is that CD4+ T regulatory (Treg) cells limit immunopathologic tissue 
damage, but may also function to help M. tuberculosis establish a persistent infection. 
 In addition to pro-inflammatory actions, CD4 T cells can also be immunoregulatory.  
CD4+CD25+ T regulatory cells were first defined by Sakaguchi et al and shown to be necessary 
to prevent autoimmune diseases [147]. Tregs dampen the immune response by cell to cell 
contact, secretion of anti-inflammatory cytokines such as IL-10 and TGF? and can limits IL-2 
availability [212].  In addition to the expression of CD25, Tregs have also been reported to 
express CTLA-4 (CD152), glucocorticoid-induced TNFR related protein, and CD39 [163].  
However, all of these surface markers are also associated with activated pro-inflammatory CD4 
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T cells and are expressed during T cell activation. To date the most definitive marker of Tregs is 
the transcription factor Foxp3 [148].  Tregs are reported to play a role in the establishment of 
persistent viral [165], parasitic [164, 168] and bacterial infections [213, 214].  However the role 
they play in the immune response to M. tuberculosis remains unclear.   
Studies in humans show that immediately following M. tuberculosis infection, the 
frequency of Tregs in peripheral blood decreases and they are hypothesized to migrate to areas of 
infection and limit tissue damage [215].  As infection progresses, a higher frequency of Tregs in 
peripheral blood is associated with individuals who have active disease when compared to either 
healthy uninfected or latently infected controls [177-179, 216, 217].  In both humans and mice, 
Tregs have been found at the site of M. tuberculosis infection [170, 218].  In addition, Tregs 
expand in the draining lymph nodes, and when depleted in a bone marrow chimera model have 
been associated with modest decreases in bacterial burdens in the lungs [171].  In yet another 
study, bacterial burden was reduced below the limit of detection or significantly decreased when 
lymphopenic animals were reconstituted with naïve non-Treg CD4 T cells when compared to 
animals that had received both Tregs and non-Tregs [176].  We sought to determine whether 
Tregs present during early M. tuberculosis infection function to limit the immune response to the 
bacilli and subsequently contribute to persistence of the infection.  
Foxp3 has been shown to be the definitive marker for Tregs.  It is an intracellular 
transcription factor, and therefore cannot be used to deplete the Treg populations within a mouse.  
Thus CD25 was the marker I chose to target Tregs for depletion in naïve mice.  Three distinct 
approaches to eliminate the CD4+CD25+ Tregs from mice prior to infection were used.  First, an 
adoptive transfer method in which RAG1-/- mice were reconstituted with whole splenocyte 
populations with or without CD25+ cells.  In a subsequent experiment RAG1-/- mice received 
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CD4+ T cells only, with or without the CD4+CD25+ population.  Finally, CD25+ cells were 
depleted with anti-CD25 antibody prior to infection in wild type mice.  Regardless of the 
experimental design, no significant reduction in the bacterial burden was found indicating that at 
least in the murine model of M. tuberculosis infection, global elimination of CD25+ Tregs prior 
to infection does not alter the immune response sufficiently to prevent M. tuberculosis from 
becoming a persistent chronic infection in mice. 
4.2 MATERIALS AND METHODS 
4.2.1 Animals  
As previously described in chapter 3, RAG1-/- and C57BL/6 mice were obtained from 
Jackson laboratories or maintained in an in-house breeding facility.  Animals were free fed a diet 
of mouse chow and autoclaved water and maintained as per the University of Pittsburgh 
Institutional Animal Care and Use Committee.   
4.2.2 Probiotic Pre-treatment of RAG1-/- mice 
To prevent the development of reconstitution induced inflammatory bowel disease[207, 208], 
RAG 1-/- mice were prophylactically treated for 14 days with probiotics.  Prior to adoptive 
transfer, mice received one scoop of Bene-Bac Powder(Pet Ag Inc. Hampshire, IL) (25 million 
Colony Forming Units (CFU) per gram, Lactobacillus fermentum, Enterococcus faecium, 
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Lactobacillus plantarum, Lactobacillus acidophilus) in 350ml of fresh, autoclaved water 
everyday.  Water bottles were changed daily. 
4.2.3 Reconstitution of RAG 1-/- mice in the presence and absence of CD4+CD25+ cells 
Splenocytes were isolated from naïve C57BL/6 mice under sterile conditions.  A single 
cell suspension was achieved by crushing the spleens through a 40μm cell strainer with the back 
of a sterile 5ml syringe.  Erythrocytes were lysed by RBC lysis buffer (previously described in 
chapter 3) and cells washed and pelleted.  Following enumeration by trypan blue exclusion, the 
splenocytes were split into two portions.  CD4+CD25+ cells were depleted by magnetic bead 
separation (Miltenyi) from half of the splenocytes as per manufacturer’s directions.  CD25 
depletion was confirmed by flow cytometry.  Once depleted, cells were washed once in PBS and 
resuspended in PBS at 4x10
6
 cells/ ml.  RAG1-/- mice received 1x10
6
 cells/200 μl PBS by i.v. 
tail vein injection.  One group received splenocytes without CD4+CD25+ cells and one group 
received undepleted splenocytes the day before M. tuberculosis infection.  
4.2.4 Reconstitution of RAG1-/- mice with only CD4+ T cells +/- CD4+CD25+ population 
C57BL/6 mice were treated with either anti-CD25 antibody (0.5mg/mouse, clone PC61, 
NCCC, NIAID, Bethesda, MD) or an equivalent volume of PBS (300μl/ mouse) by intra-
peritoneal (i.p.) injection 3 days prior to CD4 T cell isolation.  Splenocytes from each treatment 
group (anti-CD25 or PBS) were harvested as previously described.  Following enumeration, 
CD4+ cells were positively selected by magnetic bead separation (Miltenyi) as per manufacture’s 
instructions.  Cells were washed once in PBS and resuspended in PBS at 5x10
6
 cells /ml.  One 
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day prior to infection, RAG 1-/-mice were reconstituted with CD4+ only or CD4+and 
CD4+CD25+ cells at a concentration of 1x10
6 
cells/ mouse in 200μl PBS by i.v. tail vein 
injection. 
4.2.5 Antibody mediated depletion of CD25+ cells from C57BL/6 mice prior to infection 
Three days prior to M. tuberculosis infection, C57BL/6 mice were treated with either 
0.5mg/mouse anti-CD25 antibody (Clone PC61, NCCC, NIAID Bethesda MD) or PBS as 
injection control via interperitoneal injection.  CD25+ cell depletion was confirmed by flow 
cytometry.   
4.2.6 Aerosol infection 
M. tuberculosis was passed through mice, grown in liquid culture once and frozen in 7H9 
complete media 10% glycerol.  Immediately prior to infection, an aliquot was thawed and diluted 
in PBS 0.05% Tween 80.  Bacteria were disaggregated by cup horn sonnication.  Mice were 
aerosol infected with low dose (<50 CFU, Erdmann strain) using a nose only exposure 
aerosolizer (InTox Products, Albuquerque, NM).  Mice were exposed to aerosolized for 20 
minutes then room air for 5 minutes.  One day following infections, lungs of one mouse per 
round were crushed in 5 ml PBS-0.5% Tween-80, plated neat on 7H10 or 7H11 plates (Difco 
Laboratories, Detroit, MI) to determine the inoculum dose. 
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4.2.7 Harvest of organs for analysis 
At serial time points following infection, mice (n=4 mice per group per time point) were 
anesthetized with isoflurane and euthanized by cervical dislocation.  Organs were isolated under 
sterile conditions.  Organs were crushed in Dulbecco’s Modified Eagle Medium (Sigma-Aldrich) 
through a 40μm cell strainer with the plunger from a sterile 5ml syringe.  An aliquot of cellular 
homogenate was used for CFU determination.  Cells were then pelleted and washed.  
Erythrocytes were lysed as described previously in chapter 3 and cells were resuspended, 
counted by trypan blue exclusion and used for assay set up. 
4.2.8 Flow cytometric analysis of cellular infiltrate in lungs 
Cells were surfaced stained for CD3 (Clone 145-2C11, BD Pharmingen), CD4 (Clone 
RM4-5, BD Pharmingen), CD8 (Clone 53-6.7, BD Pharmingen) and CD69 (Clone H1.2-F3, BD 
Pharmingen) at room temperature for 15 minutes in PBS 0.5% BSA 20% mouse serum, washed 
and then fixed with 2% Paraformaldehyde (Sigma-Aldrich).  In the event that cells were stained 
for intracellular cytokine analysis, cells were stimulated with anti-CD3 and anti-CD28 antibodies 
in the presence of monensin as previously described in chapter 3.  Following stimulation cells 
were stained for surface markers and fixed in 2% PFA for 20 minutes.  To stain intracellular 
IFN? (Clone XMG1.2, BD Pharmingen), cells were permeabilized in FACS buffer with 0.2% 
saponin (Sigma-Aldrich) and stained in the same buffer for 15 minutes at room temperature. 
Cells were washed in the permeabilization buffer and fixed in 2%PFA.  The Data were collected 
on a FACS aria  (BD bioscience) and analyzed using FloJo software 8.6.3 (Treestar).   
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4.3 THE PRESENCE OR ABSENCE OF CD25+ CELLS DOES NOT CHANGE 
OUTCOME OF INFECTION WHEN LYMPHOPENIC MICE ARE RECONSTITUTED 
WITH NAÏVE SPLENOCYTES 
4.3.1 Bacterial burden is not significantly different between animals that received 
splenocytes with Tregs and those that did not receive Tregs 
We hypothesized that Tregs may be acting to limit the immune response to M. 
tuberculosis infection and thus preventing a sterilizing response.  First to determine whether the 
elimination of Tregs prior to infection would result in decreased bacterial burden, RAG1-/- mice 
were reconstituted with naïve splenocytes with CD25+ cells  (RAG+Treg) or splenocytes 
depleted of CD25+ cells (RAG-Treg) and compared to wild type (C57BL/6) and non-
reconstituted RAG 1-/- mice.  Mice were aerosol infected with low dose (<50 CFU) M. 
tuberculosis one day after adoptive transfer (Figure 12A).  Bacterial burden was assessed by 
serial dilution of organ homogenate and plated on 7H10 agar plates.  A slightly though not 
significantly, higher bacterial burden was found in the animals that received Tregs during 
reconstitution compared to those that did not.  However, this slight disparity is resolved by nine 
weeks (Figure 12B).  Analysis of an independent repeat of these test groups shows that at 6 
months post infection (Figure 12C), both experimental adoptive transfer groups have a similar 
bacterial numbers per lung and both are higher than WT controls.  These data indicate that when 
Tregs are depleted prior to adoptive transfer, a transient, but not significant difference is found 
within the first month of infection. As the infection progresses the difference is quickly resolved 
and not maintained during chronic infection. 
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4.3.1.1 The absence of Tregs does not affect survival 
We hypothesized that the lack of Tregs in the lungs may result in an aberrant immune 
response that would damage the surrounding lung and thus result in premature death in mice 
lacking Tregs.  This was not the case as both groups survived significantly longer than RAG1-/- 
mice and as long as wild type (6 months post infection) (Figure 12D), indicating that in this 
model the presence of Tregs at the beginning of infection did not affect survival. 
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Figure 12. Adoptive transfer, bacterial burden and survival 
RAG1-/- mice were reconstituted with naïve splenocytes in the presence or absence of CD4+CD25+ T cells and 
compared to non-reconstituted RAG-/- and wild type mice (A).  Bacterial burden was determined by serial dilutions 
of lung homogenate plated on 7H10 plates and is shown for early infection (B) as well as at 6months post infection 
(C). Murine survival (D) was assessed for 6 months post infection. 
4.3.1.2 Cellular infiltrate 
Analysis of the lung cellular infiltrate revealed that both CD4 (Figure 13A) and CD8 T 
cells (Figure 13B) are found in similar numbers in the reconstituted experimental groups.  The T 
cells exhibited an identical activation profile when both groups were compared (Figures 13C and 
13D).  Furthermore, macrophages (Figure 14A), dendritic cells (Figure 14B) and neutrophils 
(Figure 14C) were also found in equal numbers.  Taken together these data suggest that depletion 
of CD25 prior to infection did not change the type or quantity of cells that infiltrated the lungs 
during M. tuberculosis infection. 
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Figure 13. T cell frequency and activation in the lungs of mice reconstituted with naïve splenocytes 
T cell frequency and activation were determined by flow cytometry.  CD4 T cells (A), CD8 T cells (B), 
CD4+CD69+ T cells (C) and CD8+CD69+ T cells (D) are reported as the number of cells per lung (n=4 mice per 
group). 
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Figure 14. Monocytes found within the lung of reconstituted M. tuberculosis infected mice 
The frequency of macrophages (A), dendritic cells (B) and neutrophils (C) was determined by flow cytometry and 
reported as the total number of cells per lung (n=4 mice per group). 
4.4 RECONSTITUTION WITH ONLY CD4 T CELLS +/- CD25 CELLS 
CD4 Tregs are not the only mechanism by which the immune response is controlled and 
we hypothesized that other immune control mechanisms may be present in complete splenocytes 
that were able to control the inflammation.  To further dissect the regulatory role of these cells, 
we modified the adoptive transfer model and only transferred CD4+ T cells with or without the 
CD4+CD25+ population into RAG1-/- mice (Figure 15).  Again we analyzed the bacterial 
burden (Figure 16A), cellular infiltrate (Figure 16B and 16C) and activation state of the cells 
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(Figure 16D) and found no significant difference in any parameter analyzed.  These data indicate 
that the CD4+CD25+ population is not necessary during the initial stages of infection even when 
no other mechanisms for regulation are present. 
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Figure 15. Adoptive transfer of CD4 T cells +/- CD25+ cells 
C57BL/6 mice were treated with either anti-CD25 antibody or PBS i.p. for 3 days prior to isolation of CD4 T cells.  
CD4 T cells were isolated from both groups by anti-CD4 magnetic bead separation.  RAG1-/- mice were 
reconstituted with either CD4CC4 T cells +/- the CD25+ population.  (n=4 mice per group per time point).  
Representative flow cytometry plots are shown to depict the purity of the isolation. 
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Figure 16. Bacterial burden and cellular infiltrate in lungs of RAG1-/- mice reconstituted with CD4 T 
cells +/- Tregs 
The total bacterial burden per lung was determined by plating serial dilutions of lung homogenate on 7H10 agar (A).  
The total number of cells per lung (B) was determined by trypan blue exclusion. The total number of CD4+ (C) and 
CD4+CD69+ (D) cells per lung was determined by flow cytometry. 
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4.5 DEPLETION OF CD25+ T CELLS DURING ACUTE M. TUBERCULOSIS 
INFECTION 
To determine whether the presence of Tregs prevented clearance of M. tuberculosis infection, we 
depleted CD25+ T cells from mice prior to infection.  CD25 is the ?- subunit of the IL-2 recepter 
and is constitutively expressed on the surface of natural Tregs.   
4.5.1 Experimental set up 
Three days prior to M. tuberculosis infection, C57BL/6 mice were treated with either 
anti-CD25 antibody (0.5mg/mouse) or an equivalent volume of PBS via intraperitoneal injection 
(Figure 17A).  On day 3 a mouse from each group was sacrificed and examined for the presence 
of CD25+ cells. As is shown in Figure 1B, CD25+ cells was not seen in animals treated with the 
anti-CD25 antibody.   
 
4.5.2 Depletion of CD25+ cells does not affect bacterial burden over time 
Originally we hypothesized that deletion of the CD25+ cells (Tegs) from mice prior to 
infection would result in a more robust anti-mycobacterial response and thus in a decreased 
bacterial burden in the lungs.  Depletion of Tregs prior to infection did not change the bacterial 
burden found in the lungs (Figure 18A) 
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Figure 17. Depletion of CD25+ cells in C57BL/6 mice 
Mice were treated with either 0.5mg/mouse of anti-CD25 antibody or an equivalent volume of PBS (A) three days 
prior to M. tuberculosis infection.  (B) CD25+ cells were not visible by flow cytometry on the day of infection. 
4.5.3 Depletion of CD25+ cells does not change the number of cells in each organ 
Administration of anti-CD25 did not change the total number of cells found with the 
lungs (Figure 18B), spleen (Figure 18C) or draining lymph nodes (Figure 18D) when compared 
to those that had received the mock injections of PBS. 
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Figure 18. CFU and total cell number per organ 
The bacterial burden per lung was determined by plating serial dilutions of organ homogenate on 7H10 plates (A).  
the total number of cells per organ was determined by trypan blue exclusion for the lung (B), draining lymph nodes 
(C) and spleen (D). 
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4.5.4 Lack of CD25+ cells did not change activation state or IFN?  production in either 
CD4 or CD8 T cells 
We sought to determine whether depletion of Tregs would change the activation profile 
of T cells during the course of the immune response.  The early activation marker CD69 was 
used as an indicator of activation on both CD4 T cells and CD8 T cells.  Again no differences 
between groups were observed in either the lungs or lymph nodes (Figure 19A-D).  
Finally we evaluated the frequency of IFN? producing T cells within the CD4 and CD8 T 
cell compartments.  The overall frequency of IFN?+ CD4 or CD8 T cells remained exactly the 
same between the groups in both organs (Figure 20A-D).  These data indicate that depletion of 
CD25+ cells prior to infection did not change the kinetics of the immune response or the ability 
of these cells to produce the pro inflammatory cytokine IFN?.  
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Figure 19 T cell activation in the lungs and draining lymph node 
The early activation marker CD69 was used as an indicator of recent T cell activation.  CD4+CD69+ cells in the 
lungs (A) and lymph node (B) as well as CD8+CD69+ cells in the lungs (C) and lymph nodes (D) were measured by 
flow cytometry and reported as a frequency within the respective T cell compartments. 
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Figure 20. IFN?  production by CD4 and CD8 T cells in lung and lymph node 
Cells from lungs and draining lymph nodes were stimulated with anti-CD3 and anti-CD28 antibodies for 6 hours in 
the presence of monensin.  IFN? production was measured by intracellular cytokine staining and flow cytometry.  
The frequency of CD4+IFN?+ in the lungs (A) and lymph node (B) and the CD8+IFN?+ cells in the lungs (C) and 
lymph node (D) are reported as a frequency of either the CD4 or CD8 T cell compartments respectively. 
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4.6 DISCUSSION 
Regulatory T cells are essential for maintaining a balanced immune response and prevention of 
autoimmunity.  Multiple studies report the role Tregs play in the establishment of persistent 
chronic infections from multiple pathogens [164-166, 168, 169, 213, 219].  In addition, Tregs 
have been found at the site of infection in both humans and mice [170, 218] and are reported to 
limit M. tuberculosis specific IFN? production by effector cells within the blood of patients with 
active disease.  What role Tregs have and whether they function to the benefit or detriment of the 
host has yet to be defined for Tregs in tuberculosis.   
One hypothesis is that Tregs are detrimental to the host by limiting the pro-inflammatory 
Th1 response and preventing clearance of the bacilli by a sterilizing immune response.  
However, Tregs may benefit the host by limiting the immunopathologic damage to surrounding 
tissue.  To address what role Tregs may play in M. tuberculosis infection, three distinct 
experimental approaches were used.  My data demonstrate that global systemic elimination of 
CD4+CD25+ T regulatory cells prior to infection had little to no effect on the immune response 
or infection outcome.  In one experiment, lack of Tregs resulted in a mildly transient, but not 
significant reduction in bacterial burden during early infection that resolved by the chronic phase 
of infection. 
Interestingly our data are supported by data presented by Quinn et al [175], found that 
depletion of CD25+ cells prior to infection resulted in an increased IFN? response but did not 
result in a change in bacterial burden or result in clearance of the bacilli.  These data are in 
contrast to experiment in a bone marrow chimera model and used a Thy1.1/1.2 disparity to 
deplete Tregs.  Most likely the difference in outcomes can be explained by the timing and 
method of Treg depletion.  Since CD25 is the ? subunit to the IL-2 receptor and is upregulated 
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on newly activated effector T cells, we were limited by when and how often we could use an 
anti-CD25 antibody to deplete the actual Treg population without affecting expanding effector T 
cells.  In addition, the use of a Thy1.1/1.2 disparity to eliminate the Treg population could be 
used multiple time and thus keep the Treg population depleted for longer periods of time over the 
course of infection.  Finally, the data from experiments in which only CD4 T cells were 
adoptively transferred showed a modest half log decrease in bacterial burden by 7 weeks p.i. in 
mice that did not receive Tregs.  These data are in contrast to data reported by Kursar et al [176] 
in which mice that did not receive Tregs had either a 1000-fold decrease in bacterial numbers or 
cleared the pathogen.  On possible explanation for why our data were unable to duplicate the 
biphasic response to infection outcome may be because we utilized a more physiologic 
concentration of Tregs compared to the 10X greater frequency of Tregs used by Kursar et al.   
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5.0  LONG TERM IL-12 TREATMENT DURING EARLY M.TUBERCULOSIS 
RESULTS IN AN INCREASED FREQUENCY OF REGULATORY T CELLS AT SITES 
OF INFECTION 
5.1 INTRODUCTION 
Interleukin-12 (IL-12) is an essential component of an effective immune response against M. 
tuberculosis infection.  This heterodimeric cytokine (p70) is made up of the subunits p40 and 
p35 which signals through the IL-12 receptor (IL-12R?1/IL-12R?2).  IL-12 promotes a T helper 
1 phenotype immune response and is produced by dendritic cells and phagocytes following 
pathogen infection or exposure to inflammatory cytokines [220].  When T cells, NK cells and 
NKT cells become activated the IL-12R?2 subunit is up regulated and IL-12 promotes IFN? 
production by these cells.  In conjunction with other pro-inflammatory cytokines such as IL-2, 
IL-18 and IL-27, IL-12 increases IFN? production by T cells [115, 220].   
Humans with genetic mutations in IL-12 signaling (most commonly through loss of 
function mutations in the receptor complex) have an increased susceptibility to mycobacterium 
infections, even Mycobacterial spp. considered less pathogenic such as M. avium [115].  In 
addition, studies of mice lacking IL-12 (p40-/- or p35-/- or p40/p35-/-) succumb to infection [79, 
221].  Neutralization of IL-12 by antibody has also been shown to correlate with a decrease in 
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IFN? production and increased mortality in the host [80, 222].  In mice lacking IL-12, the 
susceptibility to M. tuberculosis can be reversed by exogenous delivery of IL-12 [80, 222].  
IL-12 has been studied as an immunotherapeutic for cancer [223] and some viral 
infections such as HIV [224].  In addition, IL-12 administration to BALB/c mice [73] and CD4-
/- infected with M. tuberculosis improved survival and decreased bacterial burden [225].  While 
IL-12 therapy had promising results during intra-tumor injections in mice and humans, long-term 
treatment had the potential to result in toxicity and death [223].  The reason for this moribund 
outcome could be linked to excessive IFN? production [223].  However, counter-intuitively, 
multiple reports indicate that IL-12 may be immune suppressive [224, 226-229].  Previously, our 
lab reported that long term IL-12 administration during M. tuberculosis infection of wild type 
mice failed to change bacterial load in the lungs, but resulted in a decreased cellular infiltrate and 
less area of the lung involved in inflammation.  In this chapter we attempt to discern the 
mechanism by which IL-12 decreases the immune infiltrate into M. tuberculosis infected lungs 
without affecting bacterial burden.   
5.2 MATERIALS AND METHODS 
5.2.1 Animals 
8-week-old C57BL/6 wild type mice and IL-10-/- (B6.Cg-IL10
tm1cgn
) were obtained from 
Jackson laboratories (Bar Harbor, ME) and housed under bio safety level 3 conditions in micro-
isolator cages.  Mice were free fed a diet of mouse chow and autoclaved water.  All animal care 
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was in compliance with the University of Pittsburgh’s institutional animal care and use 
committee. 
5.2.2 IL-12 treatment 
One day prior to M. tuberculosis infection and then three times a week (Monday, Wednesday 
and Friday) for up to 8 weeks p.i., mice were treated with either IL-12 (200ng/mouse, 
Genentech/Wyeth/Pfizer pharmaceuticals, New York, NY) or an equivalent volume of phosphate 
buffered saline via intra-peritoneal (i.p.) injection.   
5.2.3 Anti-TGF?  treatment 
In one series of experiments mice were treated, 3 times a week with the pan anti-TGF? antibody 
0.15 μg/mouse/ treatment (Clone 1D11, NCCC, Bethesda, MD) i.p.  These treatments were in 
conjunction with IL-12 or PBS mock treatments.   
5.2.4 Aerosol infection 
M. tuberculosis was passed through mice, grown in culture once and frozen in 7H9 complete 
media 10% glycerol.  Immediately prior to infection, an aliquot was thawed and diluted in PBS 
0.05% Tween 80.  Bacteria were disaggregated by cup horn sonnication.  Mice were aerosol 
infected with low dose (<50 CFU, Erdman strain) using a nose only exposure aerosolizer (InTox 
Products, Albuquerque, NM).  Mice were exposed to aerosolized M. tuberculosis for 20 minutes 
then room air for 5 minutes.  One day following infections, lungs of one mouse per round were 
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crushed in 5 ml PBS-0.5% Tween-80, plated neat on 7H10 plates (Difco Laboratories, Detroit, 
MI) to determine inoculum. 
5.2.5 Organ harvest and cellular isolation 
At serial time points, mice were anaesthetized with isoflurane and euthanized by cervical 
dislocation.  Organs were recovered under sterile conditions.  To obtain single cells suspensions, 
organs were crushed in Dulbecco’s modified eagle’s medium, through a 40μm cell filter with the 
back of a sterile 5ml syringe.  Erythrocytes were eliminated from the cell pellet by incubating in 
RBC lysis buffer (described in chapter 3) for 2 minutes at room temperature.  Followed by 
washing and trypan blue enumeration as previously described in chapter 3. 
5.2.6 Bacterial burden 
Bacterial burden was determined by plating serial dilutions of organ homogenate on 7H10 agar 
plates (Difco).  Plates were read after 21 day incubation at 37°C 5% CO2.  Bacterial burden was 
calculated and reported as CFU/ organ.  For statistical analysis, CFU were log transformed to 
normalize the data. 
5.2.7 Flow Cytometry 
Cells were stained as previously described for both surface and intracellular cytokine staining in 
chapters 3 and 4.  Foxp3 staining was carried out as per eBioscience Foxp3 staining kit 
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instructions.  Data was collected on a FACS aria (BD bioscience) and analyzed using FlowJo 
(8.6.3, Treestar). 
5.2.8  Statistics 
To determine significance between two groups a student-t test was used.  When more than two 
groups were compared the significance was determined by Analysis of variance.  If ANOVA 
was determined to be significant, Bonferroni post-hoc analysis was used to determine pair 
significance.  Significance was assigned when p<0.05.   
5.3 RESULTS 
5.3.1 Long term IL-12 treatment during early M. tuberculosis infection results in a 
greater frequency of CD4+Foxp3+ T regulatory cells in wild type mice 
Previously data published by our laboratory reported that IL-12 treatment during the first two 
months of M. tuberculosis infection resulted in a decreased cellular response at the site of 
infection without a decreased bacterial burden.  We hypothesized the decreased cellular response 
may be due to an increased presence of Tregs.   
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5.3.1.1 Cellular infiltrate at the site of infection is decreased in IL-12 treated animals when 
compared to those that received PBS 
To test our hypothesis, one day prior to M. tuberculosis infection, C57BL/6 mice were 
treated with either IL-12 (200ng/mouse) or an equivalent volume of PBS via i.p. injection.  At 
serial time points following infection, lungs and draining lymph nodes were harvested and the 
total number of cells per organ determined (n=4 mice per group).  As previously reported, mice 
treated with IL-12 had significantly fewer cells in both the lungs (Figure 21A) and lymph nodes 
(Figure 21B) [225].   
5.3.1.2 IL-12 treatment does not change bacterial burden 
At the time of harvest an aliquot of organ homogenate was serially diluted and plated on 
7H10 agar plates to determine the bacterial burden in the lungs and lymph nodes of infected 
animals.  With most infections, the presence of more antigen often results in increased 
inflammation with an enhanced immune response and has been shown in M. tuberculosis 
infection [97].  Thus one would expect a decreased bacterial burden in mice treated with IL-12, 
since fewer cells were recovered from the infected tissues. However this was not the case. 
Bacterial burdens were the same during the first weeks post infection in the lungs (Figure 21C). 
During later time points, PBS recipient mice exhibit a statistically significant lower bacterial 
burden.  However, it was only a decrease of 5-fold, which is relatively modest in the murine 
tuberculosis model.  Bacterial burden was comparable in the draining lymph nodes (Figure 21D).  
These data indicate that IL-12 treatment decreases inflammation without affecting the amount of 
antigen (bacteria) present. 
 88 
CFU/ lung
0 2 4 6 8 10
10
1
10
2
10
3
10
4
10
5
10
6
10
7
IL-12
PBS
*
*
*p<0.05weeks post infection
CFU LN
0 2 4 6 8 10
10
-2
10
-1
10
0
10
1
10
2
10
3
10
4
10
5
IL-12
PBS
weeks post infection
**
**p<0.01
Total number of cells/lung
0 1 2 3 4 5 6 7 8
0
1.0x10
6
2.0x10
6
3.0x10
6
4.0x10
6
IL-12
PBS**
**p<0.01weeks post infection
number of cells/ LN
0 1 2 3 4 5 6 7 8
0
5.0x10
6
1.0x10
7
1.5x10
7
2.0x10
7
2.5x10
7
IL-12
PBS
*
*
*p<0.05weeks post infection
A. B.
C. D.
 
Figure 21. Cellular infiltrate and bacterial burden in IL-12 and PBS treated wild type mice 
Wild type C57BL/6 mice were treated one day prior to M. tuberculosis infection and then three times per week p.i. 
with 200ng/mouse of IL-12 or and equivalent volume of PBS.  To determine the bacterial burden and total number 
of cells per organ, lungs and lymph nodes were harvested at serial time points.  The total number of cells per lung 
(A) and lymph node (B) were determined by trypan blue exclusion.  Bacterial burden was determined by plating 
serial dilutions of organ homogenate on 7H10 agar plates and are reported as colony forming units per lung (C) or 
lymph node (D).  Statistical significance was determined by student-t test and a p<0.05 was considered significant. 
5.3.1.3  IL-12 treatment results in fewer CD4 T cells producing IL-2  
IL-2 is a critical factor needed to initiate and sustain an adaptive immune response.  Thus 
to determine whether the decreased cellular response may be due to fewer cells producing IL-2, 
the frequency of CD4+IL-2+ T cells were analyzed by flow cytometry.  Mice that received IL-12 
had fewer CD4 T cells that produced IL-2 first in   the lymph nodes (Figure 22A) and at later 
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time points in the lungs (Figure 22B), suggesting that IL-2 production may be limited with IL-12 
treatment.  
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Figure 22. IL-2 producing CD4 T cells in the lungs and lymph nodes 
Cells from the lymph nodes (A) and lungs (B) of infected mice were stimulated with anti-CD3 and anti-CD28 in the 
presence of monensin for 5 hours.  Following stimulation cells were stained for surface markers and intracellular 
cytokines.  The frequency of IL-2+ CD4 T cells was obtained by gating cells on live cell gate, lymphocyte gate, and 
then CD4+ gate.  Data are reported as a frequency of CD4 T cell gate. 
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5.3.1.4  IL-12 and Tregs  
IL-12 treatment resulted in a decrease in the number of immune cells found at the site of 
infection without a decrease in antigenic burden.  Tregs can inhibit IL-2 production by T cells 
and fewer CD4 T cells produced IL-2 in IL-12 treated animals.  Taken together these data lead us 
to ask whether Tregs may play a role in the reduced inflammation seen in IL-12 treated mice.   
Cellular infiltrates were analyzed by flow cytometry for Foxp3+CD4+ cells within the 
lungs and lymph nodes of infected mice over time and can be seen in representative plots (Figure 
23A).  Interestingly, IL-12 treated mice had a significantly higher frequency of CD4+Foxp3+ T 
cells first in the lymph nodes (Figure 23B) and then the lungs (Figure 23C).  These data indicate 
that Tregs may expand in the lymph nodes and migrate to the lungs.  In addition, the increased 
frequency of Tregs in IL-12 treated mice may contribute to the decreased inflammation in these 
animals. 
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Figure 23. Regulatory T cells and IL-12 treatment 
Cellular infiltrate from the lungs and lymph nodes of IL-12 and PBS treated mice were obtained at serial time 
points.  To assess the frequency of Tregs present, cells were stained for CD3, CD4, CD25 and Foxp3. (A) 
Representative plots of CD25 vs. Foxp3 within the CD4 gate over time. The frequency of Tregs (CD4+Foxp3+ 
cells) within the CD4 gate is shown for lymph node (B) and lung (C).  Statistics were determined by Student T test 
and a p<0.05 was considered statistically significant. 
5.3.1.5  TGF?  and IL-12 treatment 
Transforming growth factor ? (TGF?) has been shown to be important for the induction 
and function of Tregs [230] and TGF?+CD4+ cells are reported to accumulate in the lungs of M. 
tuberculosis infected mice [170].  To assess whether immune regulation by IL-12 was associated 
an increased frequency of CD4+TGF?+ cells, cellular infiltrate was analyzed by flow cytometry.  
Analysis of CD4+TGF?+ T cells within the CD4 T cells compartment showed that at two weeks 
post infection, the frequency of these cells was significantly increased in the lymph nodes 
(Figure 24A) and lungs (Figure 24B).  However this difference was transient and no difference in 
the expression of TGF? was seen past two weeks (data not shown). 
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Figure 24. CD4+TGF?+ cells and IL-12 treatment 
Cellular infiltrate from the lymph nodes (A) and lungs were stained for CD3, CD4 and TGF? expression.  The 
frequency of CD4+TGF?+ at two weeks post infection are reported within the CD4 T cell gate.  Statistical 
significance was determined by student t-test and a p<0.05 was considered significant. 
5.3.2 IL-12 immune suppression is independent of IL-10 
IL-12 treated C57Bl/6 mice have fewer cells (less inflammation) at the site of infection without a 
decreased antigenic burden.  This difference is associated with fewer CD4 T cells that produce 
IL-2, an increased frequency of CD4+TGF?+ cells (at least in the beginning of the response) and 
an increased frequency of Tregs that start in the lymphocytes and appear to migrate to the lungs.  
Since IL-12 and IL-10 have been shown to each regulate the function of the other [231], we 
sought to determine whether IL-12 treatment associated immune regulation was dependent upon 
IL-10.  To address this question, IL-10-/- mice were treated with IL-12 and examined for 
bacterial burden, total cell numbers and frequency of regulatory T cells.   
5.3.2.1 IL-12 treatment of IL-10-/- mice did not affect bacterial burden 
IL-12 treatment did not change the total bacterial count found in the lungs of IL-10-/- 
mice when compared to PBS mock treated mice (Figure 25A).  In addition, a similar amount of 
bacteria were found within the lymph nodes of animals from both experimental groups (Figure 
25B).  
5.3.2.2 IL-12 treatment decreases cellular infiltrate  
If IL-12 mediated immune regulation were mediated by IL-10, IL-12 treated mice would 
not have decreased cellular infiltrate compared to PBS treated mice.  The total number of cells 
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per lymph node (Figure 25C) and lungs (Figure 25D) were determined by trypan blue exclusion.  
In both sets of organs, IL-12 treatment resulted a significant reduction in the number of cells 
following infection. These data indicate the IL-12 immune suppression is not mediated by IL-10. 
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Figure 25. CFU and total cell numbers in IL-12 treated IL-10-/- mice 
IL-10-/- mice were treated as described in materials and methods.  CFU was determined by plating serial dilutions of 
organ homogenate from lung (A) and lymph node (B) on 7H10 agar plates and is reported as CFU/organ.  The total 
number of cells recovered from each organ was determined by trypan blue exclusion and reported as total number of 
cells per organ.  Statistical significance was determined by student-t test and p<0.05 was considered to be 
significant. 
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5.3.2.3 Tregs and TGF?+ CD4 T cells in IL-10-/- mice 
Finally, we sought to address whether the lack of IL-10 would affect the increased 
frequency of Tregs and TGF?+ CD4 T cells found in IL-12 treated animals as compared to PBS 
mock treated mice.  In both the lungs (Figure 26A) and lymph nodes (Figure 26B) of IL-12 
treated mice, a significantly higher frequency of Treg cells were found.  Interestingly, when we 
assessed the frequency of CD4+TGF?+ cells in IL-10-/- mice, they were present in higher 
quantities than were ever found in wild type mice, regardless of IL-12 treatment (data not 
shown).  As expected the IL-12 treated IL-10-/- mice had significantly higher frequencies of 
these cells than PBS treated in both the lungs (Figure 26C) and lymph nodes (Figure 26D).  
These data in conjunction with the results of IL-12 treatment in wild type mice suggest that IL-
12 mediated immune suppression may be due to increased Tregs or possibly an increased 
expression of TGF?+CD4+ T cells and is independent of IL-10. 
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Figure 26. Frequency of Tregs and CD4+TGF?+ cells in IL-12 treated IL-10-/- mice 
The frequency of CD4+Foxp3+ cells and CD4+TGF?+ cells were determined by flow cytometry.  Statistical 
significance was determined by student-t test and a p<0.05 was considered significant.  Lung cells were not 
available for staining at the 2-week time point for either Tregs (A) or TGF?+CD4+cells (C). 
5.3.3 Neutralization of TGF?  does not change IL-12 immune suppression 
TGF? is a pleiotropic cytokine that in very low concentrations is immune stimulatory, but in 
higher concentrations is immune regulatory.  In addition TGF? plays a role in the development 
of CD4+Foxp3+ T regulatory cells [232].  Since IL-12 treated animals presented with a higher 
frequency of TGF?+CD4+cells and Tregs, we sought to determine whether TGF? plays a role in 
the anti-inflammatory effects seen with IL-12 treatments during M. tuberculosis infection.  Based 
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on prior experiments, the increased frequency of Tregs in IL-12 treated animals begins to peak in 
the lymph nodes between 2 and 4 weeks post infection.  Thus we chose the time point of day 20 
(week 3 p.i.) to examine the effects of TGF? neutralization during IL-12 treatment.  Four groups 
of wild type C57BL/6 mice were treated one day prior to M. tuberculosis infection and then three 
days a week following infection with one of the following regimen: 1) anti-TGF? antibody 
(0.15μg/mouse)/IL12 (200ng/mouse), 2) IL-12 alone, 3) anti-TGF? alone or 4) PBS.  Groups 
were assessed for bacterial burden, total cell numbers and frequency of Tregs was assessed 20 
days post infection.  We hypothesized that IL-12 treatment may be suppressing the immune 
response through TGF? induction of Treg cells.  Neutralization of TGF? had no effect on IL-12 
treatment and results were similar to those reported in IL-12 treatment of IL-10-/- and wild type 
mice (Data not shown).  These data indicate that IL-12 immune regulation is not mediated by 
TGF? induction. 
5.4 DISCUSSION 
The heterodimeric cytokine IL-12 is essential for the development of a Th1 immune response 
and thus required for effective control of M. tuberculosis infection [79, 221, 222].  IL-12 is 
produced by antigen presenting cells upon infection with an intracellular pathogen and act on T 
cells to dampen Th2 cytokine production and promote the production of IFN? [220].  In addition, 
IL-12 had been used as an immunotherapeutic in multiple cancer and chronic infection models 
[224, 233].  Conversely, IL-12 administration has also been associated with immune suppressive 
activity.  Previous data published by our lab has indicated that IL-12 treatment during the first 
two months results in a decreased inflammation and cellular infiltrate in infected tissues, without 
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affecting the amount of antigen present.  With these experiments we sought to determine the 
factors that contribute to IL-12 mediated immune suppression.   
IL-12 administration to wild type mice resulted in a decreased frequency of IL-2 
producing CD4 T cells and an increased Treg population as well as an increased CD4+TGF?+ T 
cells.  Based on these results we first asked whether IL-10 may be responsible for the decreased 
inflammation being observed in IL-12 treated mice.  IL-10 is a potent cytokine capable of 
decreasing IL-12/Th1 mediated immune responses [231].  In addition, in multiple studies, IL-10 
has been implicated in the down regulation of M. tuberculosis specific responses [233].  More 
specifically over expression of IL-10 in a murine model of M. tuberculosis infection resulted in 
premature death [86].  To address whether the immune suppressive properties of IL-12 were 
mediated by IL-10, IL-10 deficient mice were treated with IL-12 as previously described in wild 
type mice and infected with M. tuberculosis.  Results were similar to those found in wild type 
mice indicating that IL-10 was not responsible for the immune suppression of IL-12 treated 
mice.   
Finally, we chose to address the role that transforming growth factor ? may be playing in 
the anti-inflammatory properties of IL-12.  TGF? in higher doses is anti-inflammatory and is 
produced by monocytes from individuals infected with M. tuberculosis, or upon being stimulated 
with purified protein derivative (PPD) [234, 235].  TGF? has been shown to modulate the effects 
of IL-12 [236] and is an essential component involved in the induction and selection of Tregs in 
vitro and in vivo [232].  When either wild type or IL-10 deficient mice were treated with IL-12, a 
greater frequency of CD4+TGF?+ cells and CD4+Foxp3+ cells were found in the lymph nodes 
and lungs of experimental animals.  To determine whether the reduced inflammation found in 
IL-12 treated animals was dependent upon TGF?, we used antibody neutralization in the 
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presence and absence of IL-12 treatment.  Neutralization of TGF? failed to alter the IL-12 
mediated decrease in inflammation and increased Treg frequencies, indicating that TGF? was 
not the mechanism of immune suppression.   
Independent of both IL-10 and TGF?, the mechanism by which IL-12 treatment results in 
a decreased immune response with no reduction in bacterial burden remains unknown at this 
point and requires further investigation.  It is interesting to note that in a report by Zhao et al, 
mice lacking IL-12 signaling due to IL-12receptor ?2 developed more severe disease and at a 
faster rate than control animals in a diabetes model and these outcomes were associated with less 
efficient and fewer regulatory T cells [237].  These data indicate that IL-12 may play a role in the 
development of effective immune regulation through the maintenance of Tregs.  In addition, new 
studies of regulatory T cells have revealed these cells are not a rigidly fixed population but can 
and do respond to the cytokine environment around them to even express pro-inflammatory 
cytokines [238].   
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6.0  REGULATORY T CELLS IN A CYNOMOLGUS MACAQUE MODEL OF M. 
TUBERCULOSIS INFECTION 
6.1 INTRODUCTION 
Tuberculosis is the leading cause of death by a single infectious agent [5].  Although 5-10% of 
infected persons progress to primary TB, the majority control the infection, are asymptomatic 
and considered to be latently infected (LTBI) [29]. Factors contributing to these infection 
outcomes are not well understood.  The extended chemotherapy, increase in drug resistant strains 
[239], and lack of an effective vaccine [240] make identification of factors that affect infection 
outcome imperative.   
Once infected, the host mounts a robust Th1 response, and forms a granuloma, which can 
function to contain the bacilli.  Presumably, the immune response must be controlled to limit 
damage of surrounding tissue.  There is likely a fine balance in each granuloma of effector, 
inflammatory and regulatory mechanisms.  Patients with active TB produce more anti-
inflammatory cytokines such as IL-10 [231, 241] and TGF? [241, 242], compared to LTBI, but 
whether aberrant immune modulation contributes to development of active disease is unknown.  
The CD4+ T regulatory cell (Treg) has been suggested as a possible factor in promotion of active 
TB.  
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CD4 T cells expressing CD25 are potent inhibitors of autoimmunity [147]; the transcription 
factor Foxp3 is a defining characteristic of these Treg cells [148].  Tregs inhibit inflammatory 
responses and proliferation by production of cytokines, cell-to-cell contact and inhibiting IL-2 
[163].  Natural Tregs are thought to be self-reactive and prevent autoimmunity [149]. Tregs can 
also potentiate persistence of certain pathogens [164-166, 169, 219]. 
 Recent data suggest a role for Tregs in M. tuberculosis persistence.  Removal of Tregs in 
mice resulted in decreased bacterial burden in lungs [171, 176], indicating Tregs may down 
regulate M. tuberculosis specific immune responses.  PBMCs from active TB patients had 
increased frequencies of Tregs and decreased IFN? production in response to certain M. 
tuberculosis antigens when compared to LTBI [180, 181, 216].  In vitro depletion of CD25+ 
cells in active TB patients increased M. tuberculosis specific IFN? production, suggesting Tregs 
are suppressing specific responses [180, 181, 216].  These studies are unable to differentiate 
between increased Tregs contributing to development of active TB or occurring in response to 
inflammation in active disease.  Studies with human TB patients are complicated by difficulties 
in defining time of infection, extent of disease, mycobacterial strain and size of inoculum, which 
may contribute to the quality of immune responses and disease outcome.  
To address whether an increased frequency of Tregs affects development of active disease or 
occurs in response to inflammation caused by active disease, we used a non-human primate 
(NHP) model of M. tuberculosis infection.  This is the only established model to accurately 
mimic human latent infection [29].  When cynomolgus macaques are infected with a low dose 
via bronchoscope, ~50% of animals exhibit no signs of disease despite being tuberculin skin test 
positive and are considered latently infected by six months.  The other 50% develop primary 
tuberculosis [29].  These clinical classifications were validated by pathology and bacterial 
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numbers at necropsy [30].  Using this model, we addressed the correlation between Tregs and 
outcome of infection, and the dynamics of Treg in the periphery and airways.   
6.2 MATERIALS AND METHODS 
6.2.1 Experimental animals.  
Cynomolgus macaques (Macaca fascicularis) (Alpha-Genesis, Yamassee, SC; Covance, 
Madison, WI; Valley Biosystems, Sacramento, CA), were >4 years of age, 3.5-10kg, housed in a 
bio safety level 3 facility [243], and free of TB or other infections. The University of Pittsburgh 
School of Medicine Institutional Animal Care and Use Committee approved all procedures and 
protocols. 
6.2.2 Infection of NHP  
Monkeys were infected with ~25 CFU M. tuberculosis strain Erdman as described [30, 239] by 
bronchoscopic instillation.  CFU were determined in the inoculum by plating on 7H10 agar 
(Difco Laboratories, Detroit, MI).  Infection of monkeys is confirmed by tuberculin skin test, and 
lymphocytic proliferation and IFN-? production in response to mycobacterial antigens.  Infection 
outcome was independent of age, gender and weight  (Table 1) [30]. 
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6.2.3 PBMC isolation  
Blood was collected by percutaneous venipuncture [243].  Peripheral blood mononuclear cells 
(PBMCs) were isolated by Percoll gradient (Amersham Bioscience, Piscataway, NJ). 
6.2.4 BAL Cells  
Cells were sampled from airways by bronchoalveolar lavage (BAL)[243]. 
6.2.5 Necropsy of animals 
Prior to necropsy, animals were sedated, then euthanized with sodium pentobarbital (Schering-
Plough Animal Health, Union, NJ), as described [243].  A veterinary pathologist conducted all 
necropsies; tissues and samples were obtained in a sterile fashion [30].  
6.2.6 Isolation of cells from necropsy tissue  
At necropsy, granulomatous and non-granulomatous lung and lymph node were excised [30].  
Cell suspensions were obtained by homogenizing tissues in PBS using a MediMixer (BD 
Biosciences, San Jose, CA).  An aliquot of each suspension was plated for enumeration of M. 
tuberculosis colonies.  
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6.2.7 CD25 depletion from PBMCs 
 PBMCs were stained with PE anti-CD25 (Clone M-A251, BD Pharmingen, San Jose, CA); 
CD25+ cells were isolated using anti-PE beads (Miltenyi, Auburn, CA).   
6.2.8 Lymphocyte proliferation assay  
PBMCs prior to, at 6 weeks p.i. and for depletion studies were suspended in AIM V media 
(Invitrogen, Grand Island, NY) at 200,000 cells/well in 200 μl. Cells were stimulated with 
phytohemagglutinin (PHA 5μg/ml), culture filtrate protein (CFP, NIH-NIAID Contract 
HHSN266200400091C)(10 μg/ml), or media in triplicate wells for 60 hours at 37°C, 5% CO2; 
for the final 18 hours, [
3
H]-thymidine (1μCi/well, Amersham) was added.  Cells were harvested 
onto filters and radioactive incorporation measured.  Data were reported as a stimulation index 
(SI): fold increase in cpm over unstimulated control.  
6.2.9 Flow cytometry  
PBMCs, BAL cells, and cells from tissue were surface stained for CD3 (clone SP34, BD 
Pharmingen), CD4 (clone SK3, BD Biosciences), CD25 (clone MA251, BD Biosciences) [243],  
CD39 (clone eBioA1, eBioscience), GITR (clone eBioAITR, eBioscience) and intracellular 
CTLA-4 (clone BNI3, BD bioscience), then for Foxp3 (150D [BioLegend, San Diego, CA], 
PCH101, or 236A/E7 [eBioscience]) utilizing eBioscience Foxp3 staining kit.  Data were 
collected on a FACSAria (BD Biosciences) and analyzed using FlowJo 8.6.3 (Tree Star, Inc., 
Ashland, OR). 
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6.2.10 Immunofluorescence tissue staining  
Antigen retrieval on formalin fixed, deparaffinized tissue sections was performed with High pH 
Antigen Retrieval Buffer (Dako, Carpinteria, CA) at 95°C, 20 min.  Slides were blocked with 2% 
goat serum and incubated with polyclonal rabbit anti-human CD3 (Dako) and biotinylated anti-
human Foxp3 (clone 236A/E7; eBioscience) antibodies.  Isotypes were stained using rabbit anti-
human CD3 and mouse Universal Negative Control (Dako), 4°C overnight.  Sections were 
stained with goat anti-rabbit AlexaFluor 488 and AlexaFluor 546 streptavidin conjugates 
(Invitrogen), and nuclei stained with Draq5 (Biostatus Limited).  Sections were imaged with a 
Leica TCS-SL confocal microscope (Leica Microsystems), Z projections were made with ImageJ 
(vs 1.4.0, http://rsb.info.nih.gov/ij/), and brightness and contrast adjusted with Adobe Photoshop 
7.0 (Adobe Systems). 
6.2.11 ELISPOT for IFN?  
As previously described [243], 96 well opaque filtration plates (MultiscreenHTS, Millipore 
Corp., Bedford, MA) were hydrated with sterile 35% ethanol and 1X PBS and coated with anti-
human/monkey IFN ? antibody (15μg/ml, Mabtech, Nacka Strand, Sweden).  Plates were 
incubated at 4°C overnight prior to use.  The following day, plates were washed with 1X PBS 
and blocked with RPMI and 10% human AB serum (Gemini for 1 h at 37°C 5% CO2. Duplicate 
wells were used for each condition.  Monoclonal mouse anti-monkey CD3 (30μg/ml, Biosource 
International, Camarillo, CA) was used as a positive control and media was used as a negative 
control.  Mycobacterial culture filtrate protein (CFP) (10μg/ml), and peptide pools of M. 
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tuberculosis-specific proteins ESAT-6 (Rv3875) (10μg/ml) and CFP-10 (38-1/Rv3874) (2μg/ml) 
were used to stimulate. 
 PBMC ELISPOTs were performed at 6 weeks post infection and at the time of 
necropsy.  PBMCs were added at a concentration of 2 x 10
5
 cells/well in RPMI 10% human AB 
serum. BAL cell ELISPOTS were done monthly over the course of infection.  BAL cell were 
added at a concentration of 1 x 10
5
 cells/well with 5 x 10
3
 dendritic cells/well with and without 
stimulators.  Cells were incubated at 37°C 5% CO2 for approximately 40 hours. 
 ELISPOTs were developed by serial washes with deionized water and 1X PBS 
0.01% Tween-20.  Plates were incubated with 100μl of biotinylated anti-human IFN? antibody 
(2.5μg/ml, Mabtech, Nacka Strand, Sweden) at 37°C 5% CO2 for 2 hours.  Following the 
incubation, the plates were washed multiple times with 0.01% Tween-20 in 1X PBS and 
strepavidin-horseradish-peroxidase-Q (Mabtech) was diluted 1:100 and added to each well for 1 
h at 37°C.  Spots were visualized by staining with AEC peroxidase kit as per the manufacture’s 
instructions and counted using an automatic ELISPOT reader.  Data were collected by image 
acquisition 4.5 and analyzed by Immunospot 5.0.3 (Cellular Technology Ltd. (Shaker Heights, 
OH) 
6.2.12 Statistics  
To compare two groups when data were determined to have normal distribution, a student t-test 
was used.  If data did not have a Gaussian distribution, Mann-Whitney was used for unpaired 
data and Wilcox Signed Rank for paired data.  Comparison of contiguous data over time was 
analyzed by repeated measures ANOVA and if significant, pair-wise comparison was by Tukey-
Newman tests. p<0.05 was considered statistically significant.  
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6.3 RESULTS 
6.3.1 Infection outcome is independent of age, gender and weight 
The NHP is the only animal model that mimics the spectrum of M. tuberculosis infection (latent 
and active disease) seen in humans [30].  Infection outcomes are determined by clinical criteria 
and severity of disease quantified at necropsy [30]. M. tuberculosis infection is confirmed by 
tuberculin skin test, antigen-specific 
3
H-thymidine incorporation, and IFN? production by 
ELISPOT.  Data for the monkeys used here are summarized in Table 1.  As reported in other 
studies, all non-human primates were positive for immunologic indicators of infection and 
infection outcome was independent of age, gender and weight [30]. 
 
Infection 
outcome 
Total # #M/#F Age (y/o) Weight 
(Kg) 
%+ TST %+LPA %+IFN?  
Active 19 16/3 7.7±1.7 6.0±1.3 100 100 100 
Latent 21 18/3 8.3±1.4 6.5±1.0 100 100 100 
 
Table 1.  Summary of vital statistics and immunologic assays of all non-human primates used in this 
study.   
The table summarizes the total number of animals that developed latent infection or active disease as well as the 
total number of each gender. The mean age and weight and standard deviation for each group are listed.  Following 
inoculation, non-human primates are tested for infection by skin test (TST+), lymphoproliferation (LPA) and IFN? 
production by ELISPOT (IFN?+) to M. tuberculosis antigen. 
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6.3.2 CD4+ Foxp3+ cells are found within involved and not uninvolved lung and draining 
lymph node tissue 
Cells from involved lung and thoracic LN at necropsy were stained for CD3, CD4, CD25 
and Foxp3 (Figure 27A, B).  In tissues, not all Foxp3+ cells are CD25+ and not all CD25+ cells 
are Foxp3+.  Classically, Tregs have been defined as CD4+CD25
hi
 cells.  However, CD25 is also 
found on activated effector T cells and where immune stimulation is continuous, (e.g. chronic 
infection), one is unable to distinguish Tregs from effector populations with this single marker. 
The transcription factor Foxp3 denotes a Treg phenotype [148].  In humans, Foxp3 is transiently 
expressed during priming, but transfection of constitutively active Foxp3 conferred the Treg 
phenotype [244].  CD4+Foxp3+ cells in PBMC expressed Treg-associated cell surface markers 
and did not produce cytokine in response to M. tuberculosis antigens (Figure 28).  Thus we used 
CD3+CD4+Foxp3+ to define the Treg population.   
To address whether Tregs were preferentially localized to areas of lung containing bacilli, 
tissue homogenates were divided into M. tuberculosis+ (involved) or M. tuberculosis- 
(uninvolved), based on whether M. tuberculosis was cultured from the sample.  Involved lung 
tissue (granulomas) contained a significantly higher frequency of both total CD4+ T cells (Figure 
27C) and Tregs (Figure 27D) than uninvolved lung.  Similar to murine studies [171], 
lymphocytes localized to pulmonary sites that contained M. tuberculosis.  Interestingly, when 
thoracic LN from infected NHP were divided into M. tuberculosis+ and M. tuberculosis- 
samples, involved LN had significantly fewer CD4 T cells than uninvolved LN (Figure 27E), but 
there was a trend toward more Tregs within the CD4 subset (Figure 27F).  It may be that fewer T 
cells are present in involved LN because of effacement by granulomas with caseous necrosis.  
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Figure 27. Regulatory T cells are enriched in involved lung tissue and lymph node 
The frequency of Tregs (CD3+CD4+Foxp3+) was determined by gating on live cells, lymphocytes and CD3+CD4+ 
cells in involved (M. tuberculosis+) and uninvolved (M. tuberculosis-) lung and thoracic lymph node at necropsy. 
Representative dot plots of A) involved lung and B) lymph node from an infected monkey. The frequency of CD4+ 
cells (C, E) and Tregs within CD4 gate (D, F) in lung or lymph node were compared within involved and 
uninvolved tissue. 
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Figure 28. Cellular surface markers on Tregs 
CD4+Foxp3+ Tregs were analyzed for expression of Treg associated cell surface markers at 0, 8 and 24 weeks post 
infection.  A) Shows representative plots of CD25 (B), CD39 (C), intracellular CTLA-4 (D) and GITR (E).  
6.3.3 CD4+Foxp3+ T cells are found within the lymphocyte cuff of the granuloma 
Immunofluorescent staining demonstrated that CD3+Foxp3+ Tregs are abundant within the 
lymphocyte cuff of granulomas (Figure 29), but rare in uninvolved lung.  These data support that 
Tregs preferentially localize to involved tissue (granulomas) and are proportionally increased in 
thoracic LN.  Thus Tregs may control the local immune response within granulomas. 
 111 
 
Figure 29. Regulatory T cells in granulomas 
Paraffin-embedded granulomatous lung tissue was immunofluorescently stained for nuclei (blue), CD3 (green) and 
Foxp3 (red). The 60x section is an enlargement of box indicated on merged image from 20x. 
6.3.4 Tregs migrate from peripheral blood to airways during early M. tuberculosis 
infection 
We analyzed PBMCs from 41 NHPs (infected for other studies) for six months after inoculation.  
The frequency of Tregs decreased dramatically within the first two weeks and was significantly 
lower than pre-infection levels 8-12 weeks p.i. (Figure 30A), while CD4 T cell frequencies were 
unchanged (Figure 30C).  
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The reduction in Treg frequencies in the periphery during early infection suggested that 
Tregs were migrating to the lungs.  BAL is the only relatively non-invasive way to serially 
sample the pulmonary environment.  For 6 months, BAL cells were obtained monthly from 17 
macaques and stained for Tregs (Figure 30B).  By 4 weeks p.i., the frequency of Tregs increased 
in airways, corresponding to the reduction in the periphery.  After an initial influx of Tregs into 
airways, the frequency of Tregs fluctuated until 16 weeks p.i., when both Tregs and CD4 T cells 
(Figure 30B,D) increased.  These data suggest Tregs are migrating from blood to the lungs soon 
after M. tuberculosis infection.   
6.3.5 Pre-infection levels of Tregs in PBMC correlate with clinical outcome 
Of 41 macaques followed, 22 developed active disease and 19 had latent infections. Surprisingly, 
the animals that became latent had significantly higher frequencies of Tregs prior to infection in 
PBMCs compared to monkeys that developed active disease (p=0.0116)(Figure 30E).  Although 
all NHP exhibited an initial decrease of Tregs, latently infected animals maintained higher levels 
of Foxp3+ cells compared to those with active disease at 8 weeks p.i. (Figure 30E).  By 16 
weeks, all animals returned to pre-infection levels of Tregs.  Those that would develop latent 
infection maintained pre-infection Treg frequencies, while Foxp3+ cells continued to increase up 
to 28 weeks p.i. in those developing active disease. Latent NHP demonstrate a trend of more 
Tregs in BAL by 4 wks p.i. compared with those that would develop active disease (Figure 30F), 
although this was not statistically significant.  
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Figure 30. Tregs in PBMC and airways during M. tuberculosis infection 
A) The frequency of Tregs (CD3+CD4+Foxp3+) in PBMC during M. tuberculosis infection (n=41 monkeys) was 
determined by gating on live cells, lymphocytes and CD3+CD4+ cells. B) BAL cells from infected NHPs (N=17) 
were stained and gated as above.  p <0.05 was considered significant. PBMCs and BAL cells were stained and 
compared between active disease (open squares) and latently infected (open circles) groups.  The frequency of CD4 
T cells within the lymphocyte gate (C, D) or Foxp3+ cells within CD4 gate (E, F) for blood (C, E) and airways (B, 
D) are represented. Statistical significance over time (A) was determined by repeated measure ANOVA (p<0.0001) 
with a Tukey-Newman post-test. (C-F) Mann-Whitney determined significance between each group at each time 
point. 
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6.3.6 Foxp3+ cells affect proliferative responses in peripheral blood 
To determine whether increased Tregs correlated with a reduced proliferative response, PBMCs 
were stimulated with the mitogen PHA or mycobacterial CFP.  Prior to infection, PBMCs from 
animals that would become latent demonstrated significantly less proliferation in response to 
PHA than PBMCs from animals destined to develop active TB (Figure 31A), correlating with 
more peripheral Tregs in latent monkeys (Figure 30E).  By 6 weeks p.i., the latent group 
exhibited a trend toward decreased proliferation in response to both PHA (Figure 31A) and CFP 
(Figure 31B).  Tregs were not measured at 6 weeks, but the frequency of Tregs is significantly 
increased at 8 weeks p.i. in latently infected monkeys compared to those that would develop 
active disease.  All NHPs showed increased proliferation to both stimuli by 6 weeks p.i. and had 
significantly lower frequencies of Treg compared to pre-infection by 8 weeks.  These data 
support an association between decreased proliferation and more Tregs, suggesting that Tregs 
may limit T cell proliferation.  
 We tested whether depletion of Tregs would reverse this reduced response.  No 
convenient method for depleting Foxp3+ cells from primates exists, so CD25+ cells were 
depleted from PBMC (Figure 31C). Depletion of CD25+ cells resulted in increased proliferation 
in seven of ten animals for both stimuli (Figure 31D,E).  
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Figure 31. Tregs inhibit PBMC proliferation 
PBMCs from animals that would develop active disease (shaded bars, N=22) or latent infection (open bars, N=19) at 
0 and 6 weeks p.i. were stimulated with A) PHA and B) CFP, and proliferation measured. Data reported as 
stimulation index.  Statistical significance was determined by Mann-Whitney. CD25+ cells were depleted from 
PBMCs (N=10) (C), and stimulated as above. Comparison of PBMC proliferative response to PHA (D) and CFP (E) 
before and after CD25 depletion is reported as a stimulation index statistical significance was determined by Wilcox 
Signed Rank. 
6.4 DISCUSSION 
The immune response against M. tuberculosis is a tightly controlled balance between 
sufficient inflammation to limit M. tuberculosis growth and regulatory factors that prevent 
damage of surrounding tissue.  We sought to determine whether the frequency of regulatory T 
cells in blood and airways was associated with outcome of infection in a macaque model of TB.  
We hypothesized that if Tregs were involved in modulating the immune response to M. 
tuberculosis and limiting damage to tissue, Tregs would be found at the site of infection. If 
regulatory T cells contributed to development of active disease, we would expect the following:  
First, animals that develop primary TB would have a higher frequency of Tregs in blood and 
airways prior to or during early infection when compared to those that develop latent infection.  
Second, an increased frequency of Tregs would correspond with decreased proliferation when 
PBMCs were stimulated with antigens.  Conversely, if increased Tregs were not a causative 
factor for active TB, but a response to inflammation, a disparity in Tregs would become apparent 
between the two groups when those with active disease failed to control bacterial growth.  
 117 
In healthy individuals, M. tuberculosis infection is predominantly localized to the lung 
and thoracic LN.  Bacilli and granulomas are most commonly found in lung parenchyma, rather 
than airways, making sampling involved tissues difficult.  In humans, timing of infection, as well 
as dose and strain of inoculum are unknown, and samples prior to infection are not generally 
available for comparison.  Since these factors can contribute to the quality of the immune 
response and infection outcome, we used the macaque model of TB.  This model resembles 
human TB in disease outcome and pathology, and inoculum size, strain and timing of infection 
can be controlled [239].  PBMC and BAL cells can be obtained frequently, and tissue samples 
are available at necropsy. In these studies, not all Foxp3+ cells are CD25+ and not all CD25+ 
cells are Foxp3+; we defined our Treg cell population as CD3+CD4+Foxp3+. In blood we are 
most likely measuring Foxp3+ natural Tregs [163]; cells found within airways and tissues may 
be primed before migrating to the site of infection.  Here we show that Tregs are present in 
involved lung and LN and localize to the lymphocyte cuff of granulomas, suggesting they may 
modulate immune responses within the granuloma.   
 We examined the association between Tregs in blood and airways of infected 
monkeys and development of active disease and found surprising results.  Whereas the literature 
[177, 178, 180, 181, 215] supports an association between active disease and increased Tregs in 
blood of humans, we found that monkeys who developed latent infection had a significantly 
higher frequency of Tregs in PBMC prior to and during early infection than those that developed 
primary TB.  The increased frequency of Tregs in monkeys that became latently infected 
correlated with decreased proliferation to mitogen prior to M. tuberculosis infection.  When 
CD25+ cells were depleted from PBMCs, several NHPs exhibited a modest increase in 
proliferation when stimulated with CFP and PHA. Our findings do not support the hypothesis 
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that more Tregs and a less vigorous lymphoproliferative response during the initial phase of M. 
tuberculosis infection would predispose an individual to development of primary TB.  On the 
contrary, our data indicate that more Tregs prior to infection correlates with a better infection 
outcome.  
These data led us to ask whether the increased frequency of Tregs associated with active 
disease is a response to increased inflammation.  Regardless of infection outcome the frequency 
of Foxp3+ cells dramatically decreased in blood within the first 8 weeks.  This early reduction in 
Foxp3+ cells suggests that these cells are poised to sense inflammation and migrate quickly to 
the site of infection, and mirrors a drop reported in peripheral blood of healthy human contacts in 
the Gambia [215].  At the same time, the frequency of Tregs increased in airways, supporting the 
hypothesis that these cells migrate to the lungs.  In vitro experiments on lymphocytes from both 
humans and mice indicate that natural Tregs change their chemokine receptor phenotype more 
quickly than naïve/resting T cells in the periphery [245].  This may be a mechanism for rapidly 
increasing Tregs at the infection site for expansion during the initial burst of inflammation to 
protect surrounding tissue from damage.  While all monkeys returned to baseline levels of Tregs 
in PBMC by 16 weeks p.i., those with latent infection remained steady while Tregs in NHPs with 
active disease began to increase.  
In summary, these data indicate that following infection, Tregs rapidly decrease in 
peripheral blood, and are maintained at low levels in the periphery for ~4 months.  When 
bacterial growth is under control, i.e. during latent infection, peripheral levels of Tregs return to 
pre-infection levels.  However, when bacterial growth is not contained and active disease 
develops, Tregs continue to increase, perhaps acting to dampen peripheral inflammation as a 
protective mechanism.  Based on this concept, we propose a model where Tregs in peripheral 
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blood act as important regulators poised to protect uninvolved tissues from potentially damaging 
antimycobacterial immune responses.  Upon infection Treg migrate to the lung and draining LN 
to protect “healthy” tissue and limit inflammation.  Tregs are retained within granulomas and 
involved LN along with effector T cells.  Provided the T cell response is sufficient to contain M. 
tuberculosis infection, Tregs control damage to surrounding tissue by limiting proliferation of 
effector T cells in granulomas.  In latent infection, peripheral responses are limited due to 
containment of antigen within granulomas and control of bacterial growth.  However if the 
immune response is insufficient to control bacterial replication, antigenic burden increases, 
resulting in increased inflammation.  In this instance, Tregs in the periphery may limit the 
inflammation associated with active disease.  The increased Treg frequency observed in blood of 
people with active TB is likely a response to inflammation and bacterial burden, and not a 
predetermining or contributing factor to active disease, at least during the initial stages of 
infection. 
 Control of M. tuberculosis is a dynamic balance between inflammation and 
immune regulation maintained by the host. Here we explored the role of Treg cells in the 
dynamics of this response during initial stages of infection. Further understanding of how these 
cells are functioning at the site of infection as well as the signals responsible for early exodus 
from the periphery will provide valuable information about the microenvironments needed to 
maintain control of M. tuberculosis infection. 
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7.0  SUMMARY OF THE DISSERTATION 
Mycobacterium tuberculosis is an acid fast, obligate intracellular bacteria and the 
etiologic agent of TB.  An exquisite pathogen that has been evolving with the human race for 
millennia, the effects of M. tuberculosis-mediated bone disease (e.g. Potts disease) have been 
found in the mummies of such disparate ancient cultures as Peru, Israel, Egypt and China [1-4].  
Its long history with humans has enabled M. tuberculosis to become widely distributed 
throughout the global population with an estimated 1/3 of the world’s population infected.  
While only a small percentage of those infected ever develop active disease, the potential 
reservoir for tuberculosis is enormous [9].   
The AIDS epidemic in the 1980’s brought TB back to the forefront with a vengeance 
[105].  The burden of this resurgence has been the developing world, a place that lacks sufficient 
public health infrastructure to administer DOTS therapy on a large-scale basis.  Chemotherapy is 
long and comprised of multiple chemotherapeutic agents with a plethora of side effects.  Many of 
those with disease fail to complete the treatment regimen and contribute to the development and 
transmission of the growing number of multi drug resistant and extensively drug resistant strains 
of M. tuberculosis [9, 239].  Finally lack of an effective vaccine for disease prevention and the 
development of relatively few new effective chemotherapeutic agents in the last 50 years make it 
imperative that more research is conducted to better understand what constitutes an effective 
immune response against this pathogen. 
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  M. tuberculosis is spread when droplets containing the bacilli are inhaled into the airways 
and phagocytosed by alveolar macrophages and dendritic cells.  Once inside the phagosome, 
their primary residence, the bacilli begin a complex series of interactions with the host.  
Eventually infected dendritic cells migrate from the lungs to the draining lymph nodes and prime 
an adaptive immune response.  Once primed, antigen specific CD4 and CD8 T cells migrate back 
to the site of infection and activate M. tuberculosis infected macrophages to kill some but not all 
resident bacilli.  In addition, T cells wall off the macrophages to form the granuloma. The 
granuloma, a collection of immune cells at the site of infection, protects the host by containing 
the bacteria, however it also provides a niche for the bacterium to persist [16, 190].  Thus the 
granuloma, while containing infection also becomes the site of the host: pathogen standoff.   
 Maintenance of this standoff is in the best interest of both the host and bacilli.  If the 
bacillus was to kill the host, it loses the chance to spread and continue to thrive.  In contrast the 
host must walk a fine line between sufficient inflammation to control bacterial growth and 
limiting damage to surrounding uninvolved healthy tissue.  The work presented within this 
dissertation sought to better elucidate the role CD4 T cells played in the immune response to M. 
tuberculosis.  
  CD4 T cells are essential for an effective immune response against M. tuberculosis.  
Their importance was first shown in HIV+ individuals whose incidence of TB increases as CD4 
T cell counts decrease.  Similar results have also been shown in SIV infected NHPs[105, 106].  
In addition, mice deficient in CD4 T cells fail to control infection and succumb much sooner 
than WT mice [103].  CD4 T cells are able to both promote and inhibit inflammation.  Naïve 
CD4 T cells can be primed to be pro-inflammatory and exhibit a Th1, Th2 or Th17 phenotype 
[108].  During the course of M. tuberculosis infection, both Th1 and Th17 CD4 T cells are 
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primed [144]. While Th1 cells are required for control of the bacilli, the role of Th17 has yet to 
be completely defined. Th1 cells produce IFN?, IL-2, TNF and GMCSF.  These cells act to help 
prime an effective CD8 T cell response, condition DCs to be effective APCs, and produce 
cytokines that activate macrophages to kill intracellular bacteria.  Th17 cells produce IL-17 and 
are thought to work to recruit lymphocytes and other cells into the parenchyma [108]. While a 
few CD4 T cells produce IL-17, ?? T cells are the primary source of IL-17 during the early 
course of M. tuberculosis infection [83].  Interestingly, even though both cytokines are produced, 
IFN? and IL-17 are produced by separate and distinct T cell populations.  
To determine how CD4 T cells contribute to the immune response to M. tuberculosis 
infection the work presented in this dissertation utilized both the murine and non-human primate 
models of infection.  Previous studies focused on the immune response to M. tuberculosis have 
relied heavily on knockout and transgenic mouse models in conjunction with antibody depletion 
studies.  Without question the power of these tools has been the relatively low cost and the ease 
with which the system can be manipulated.  These studies have provided valuable insight into the 
identity of key players involved in infection control (e.g. CD4 T cells [103]). However powerful, 
these approaches are limited by the loss or gain of function on a global scale and are unable to 
address the timing and source of specific components of the immune system. Here we present a 
new adoptive transfer model that allows manipulation of individual cell populations and 
addresses when and from what source important mediators of the immune response are required 
(Chapter 3).   
To determine whether IFN? from sources other than CD4 T cells was sufficient to contain 
M. tuberculosis infection we used our new model. The data suggest that both the presence of 
CD4 T cells and IFN? produced by CD4 T cells are required for host survival.  In addition, the 
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data suggest that IFN? from CD4 T cells directly affects the quality of the CD8 T cell response.  
The data indicate in the absence of IFN?, T cells can activate macrophages to limit growth, but 
not kill intracellular pathogens.  CD4 T cells that were unable to produce IFN? produced IL-17 
and prolonged host survival when compared to those lacking CD4 T cells.  However, these 
animals eventually succumb, indicating that the Th17 cells are not sufficient to contain infection.  
In addition to IFN? production, the presence of CD4 T cells is required to initiate or sustain an 
effective immune response and this is most likely due to IL-2 production. The new adoptive 
transfer model described in this dissertation will allow for future more detailed studies that 
investigate cytokine and chemokine production by specific cell types (Chapter 3). 
While the adaptive immune response is required for control of bacterial growth, the host 
must also limit the response to involved tissue to protect surrounding uninfected lung [246].  
CD4 T cells are also capable of regulating the immune response to infection as Tregs.  Natural 
Tregs are thymically selected, expand in the draining lymph node during infection and migrate to 
the site of infection once primed.  These cells are antigen specific and have been shown to 
express the Th1 specific transcription factor T-bet during priming, indicating that these cells 
expand in the presence of the Th1 cytokine milieu. 
To determine whether Tregs were important during M. tuberculosis infection, we utilized 
antibody depletion to investigate the effects of Treg elimination prior to infection.  The data 
presented indicate that elimination of Tregs prior to infection does not influence either survival 
or antigenic burden in mice (Chapter 4). Human M. tuberculosis infection results in either latent 
infection or active TB and what contributes to these disparate infection outcomes is yet 
unknown.  M. tuberculosis infection in mice is a chronic progressive infection, thus what 
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contributes to the development of either active disease or latent infection cannot be addressed 
with these models.   
To assess the relationship between Treg frequency and development of active disease or 
latent infection, we chose the non-human primate model. To date it is the only well defined 
animal model to recapitulate human infection outcomes of latent and active disease. Human 
studies have suggested that an increased frequency of Tregs contributes to the development of 
active disease [178-180, 247].  However, this association is limited to the comparison of 
individuals once infection is established, without knowing what frequency of Treg was prior to 
infection.  Studies in humans are also limited by not knowing the size and strain of the inoculum, 
the length of infection and the immune status of the host, all of which can affect the immune 
response to M. tuberculosis infection.  In addition, studies are limited to what types of imaging 
(X-ray, MRI, CT-PET scan) and samples (BAL, PBMC) can be obtained easily and safely.  Thus 
with human studies alone, one is not able to determine whether Tregs predispose an individual to 
develop active disease or whether Tregs increase in frequency in response to the inflammation 
found in those with active disease.  In NHP, regardless of infection outcome, within two weeks 
of infection, Tregs decrease dramatically in the peripheral blood and increase in the airways.  We 
speculate that this early migration to infected tissues may be to limit possible damage to the lung 
tissue and control inflammation at the site of infection.  Interestingly, a higher frequency of 
Tregs prior to infection correlated with the development of latent infection.  However, once 
infection was established, NHP with active disease exhibited increasing frequency of Tregs in 
the peripheral blood (Chapter 6).  Taken together, these data show that a higher frequency of 
Tregs prior to infection correlated with a better infection outcome and the increased frequency of 
Tregs found in those with active disease occurred once active disease was established [248].  
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These experiments challenge the notion that Tregs predispose the host toward development of 
active disease and introduce the idea that regulation of the immune system may be important in 
maintaining the host: bacilli standoff. 
Finally, our laboratory has previously published that long term IL-12 treatment of mice 
during the first two months of M. tuberculosis infection results in decreased cellular infiltration 
into infected tissues without decreased bacterial burden [225].  These results suggest that IL-12, 
while an essential cytokine in control of this infection, may have anti-inflammatory properties in 
addition to pro-inflammatory ones.  Here we show that IL-12 treatment results in decreased 
cellular infiltrate associated with an increased frequency of Tregs that is independent of bacterial 
burden (Chapter 5).  Thus while the presence of Tregs in a chronic progressive infection may not 
alter host survival, they may play a role in limiting damage sustained in surrounding uninvolved 
tissues.  These data provide new insight about what is necessary and needed for a sufficient 
appropriate immune response to M. tuberculosis infection.  These results add to the growing 
body of literature that report that immunoregulatory responses maybe as important as the pro-
inflammatory ones during infection to prevent immunopathologic damage to healthy tissues.  By 
priming the immunoregulatory response at the same time as the pro-inflammatory immune 
response, the host is in effect laying the groundwork for peace while waging the war. 
Based on our data and recently published literature, we propose that an effective immune 
response is one in which the pro-inflammatory response is balanced effectively with the 
immunoregulatory response, presumably resulting in latent infection.  If one of the responses is 
out of balance, for example too much inflammation, one might expect to see damage to 
surrounding healthy tissue or erosion of the granuloma into an airway, thus allowing the bacilli 
to escape when the host coughs.  In contrast if the host mounts too much of an immunoregulatory 
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response, one might expect that the host is unable to control bacterial growth and may develop 
active disease.   
To date, we lack an effective vaccine for prevention of M. tuberculosis infection and the 
development of active disease.  BCG, the current gold standard vaccine has been in use for 90 
years and has variable efficacy.  In addition, co-infections in endemic areas influence the 
outcome of vaccination.  Thus better understanding of what constitutes an effective response 
against M. tuberculosis is imperative.  Traditionally, vaccination of many diseases has resulted in 
sterilizing immunity; this may not be possible with vaccination against M. tuberculosis.  
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